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ABSTRACT 
 
Sunni Lyn Mumford: The interplay between hormones, lipids, and dietary intake:  
The BioCycle Study 
(Under the direction of Anna Maria Siega-Riz) 
 
Background:  Exogenous estrogens (i.e. hormone therapy and oral contraceptives) have 
been shown to affect the lipid profile, leading to the hypothesis that endogenous estrogens 
may have similar effects.  However, the relationship between estrogens and lipoproteins is 
complex, especially given that cholesterol is the initial precursor for steroid biosynthesis and 
dyslipidemia has been associated with altered hormone levels and anovulation.  The effects 
of baseline cholesterol levels on anovulation are also not well understood.  As fiber intake 
lowers both estrogen and lipoproteins, it is unknown whether estrogen may mediate the effect 
of fiber among premenopausal women.  
Methods:  The BioCycle study was a prospective cohort of 250 self-reported regularly 
menstruating women aged 18 to 44, followed for two menstrual cycles.  Lipoprotein 
cholesterol and hormones were measured in serum collected at up to 16 visits timed using 
fertility monitors.  Marginal structural models with inverse probability of exposure weights 
were used to model the associations of interest. 
Results:  Estradiol was positively associated with HDL cholesterol in acute effects models, 
and inversely associated with total and LDL cholesterol and triglycerides in persistent effects 
models.  Total cholesterol levels preceding the predicted time of ovulation were weakly 
associated with an increased risk of anovulation, and luteinizing hormone:follicle-stimulating 
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hormone ratio, sex hormone binding-globulin, insulin, and acne were identified as significant 
predictors of anovulation.  Fiber consumption at or above 22 g/day was associated with lower 
total and LDL cholesterol, independent of estrogen, however the controlled direct effect was 
reduced at high levels of estrogen. 
Conclusions:  Our results support the hypothesis that estrogen exerts beneficial effects on 
lipoprotein cholesterol levels and sheds light into the timing of these effects. The more 
atherogenic lipid profile and endocrine characteristics indicative of hyperandrogenism among 
anovulatory women are indicative of a mild undiagnosed phenotype of polycystic ovary 
syndrome, however further research is needed to elucidate the biological mechanisms.  The 
reduced controlled direct effects of fiber on cholesterol at higher estrogen levels suggest that 
estrogen decreases fiber’s effect among premenopausal women.  Cycle phase should be 
considered in the design and interpretation of studies in women of reproductive age due to 
estrogen’s influence on many biological processes. 
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I. INTRODUCTION 
Coronary heart disease (CHD) is the leading cause of death among women, primarily 
affecting postmenopausal women.1  The prevalence of CHD among women 20 to 39 years 
old is half the rate among men in the same age group (women, 7.8%; men, 15.9%). The 
difference in prevalence of CHD between men and women holds despite adjustment for 
various risk factors.  However, as the prevalence of CHD among women increases with age, 
the difference between men and women drastically narrows.1 This has led to the hypothesis 
that circulating endogenous estrogens protect premenopausal women from CHD.  With this 
in mind, hormone therapy was recommended to postmenopausal women as a means of 
cardio-protection.2-5  However, results from the Women’s Health Initiative (WHI) trial6 and 
the Heart and Estrogen/progestin Replacement Study (HERS)7 found that hormone therapy 
improved lipoprotein profiles but was associated with increased rates of CHD, which 
suggested that the role of exogenous/endogenous hormones on CHD was more complicated 
than originally thought. 6-8     
The associations between exogenous sex hormones and lipoproteins seem to be well 
established.  Estrogen is thought to exert a favorable effect on lipoprotein metabolism by 
increasing very low density lipoprotein (VLDL) synthesis, inhibiting hepatic lipase and 
lipoprotein lipase activity, and upregulating the low-density lipoprotein (LDL) receptors.9-11  
The effect of endogenous sex hormones on lipoprotein levels in healthy premenopausal 
women however, remains uncertain, as well as whether these effects are chronic versus acute.  
Studies of lipoprotein metabolism during the menstrual cycle have yielded conflicting results, 
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and have failed to take into account circulating levels of other reproductive hormones such as 
progesterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) throughout 
the menstrual cycle, which could impact the association between estrogen and lipoprotein 
cholesterol levels.  Understanding variations in lipoprotein cholesterol levels is important 
because there may be clinical implications regarding the appropriate timing of measurement 
during the cycle, as well as implications on the design and interpretation of studies in women 
of reproductive age.  Further information regarding the effect of endogenous estrogen on 
lipoprotein metabolism may also help elucidate estrogen’s role in protection against 
atherosclerosis. 
Not only are lipoprotein levels influenced by reproductive hormones, but total 
cholesterol is the initial precursor for steroid biosynthesis of sex hormones such as 
progesterone, estrogen, and testosterone.  Reproductive hormone levels are intricately tied to 
ovulation through regulation of the hypothalamic-pituitary-ovarian axis.  Sporadic 
anovulatory cycles may be fairly common among regularly menstruating women, although 
they are difficult to detect and the prevalence of anovulation has not been well described.12  
The factors associated with anovulatory cycles are also not well understood among regularly 
menstruating women, but are of interest as sporadic anovulation might be associated with 
delayed time to pregnancy.  As cholesterol plays a central role in the synthesis of sex 
hormones, lipoprotein cholesterol are hypothesized to be associated with anovulation.12  To 
our knowledge the association between lipoprotein cholesterol levels and anovulation has not 
been directly evaluated.  Moreover, these relationships have not been prospectively evaluated 
in regularly menstruating women, free of diagnosed ovulatory disorders such as polycystic 
ovary syndrome (PCOS).13   
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When studying lipid levels it is also important to consider dietary intake.  
Specifically, dietary factors such as fiber and fat intake have been shown to have an impact 
on serum cholesterol and lipoprotein levels.14, 15  In fact, decreases of up to 20% in serum 
cholesterol have been observed with high fiber diets.16, 17  This decrease is usually due to a 
reduction in LDL cholesterol.  High-density lipoprotein (HDL) and triglyceride levels do not 
typically show the same effects.   
However, there is evidence that pre-and post-menopausal women respond differently 
to fiber intake,18, 19 with premenopausal women showing smaller reductions in lipoprotein 
cholesterol levels in response to fiber intake.  It has therefore been hypothesized that estrogen 
could potentially mediate the effect of fiber on lipoprotein cholesterol levels in 
premenopausal women.  High fiber intake has been associated with lower levels of 
estradiol,20-27 a result also confirmed in the BioCycle study in premenopausal women.28  
Since estrogen and lipoproteins are intrinsically linked, as estrogen stimulates lipoprotein 
metabolism and cholesterol is the precursor for steroidogenesis, the implications of fiber’s 
association with estrogen on lipoprotein metabolism is evident.  To date, however, there has 
been little research on how much of the observed effect of fiber on lipoprotein cholesterol 
levels is working independently, and not mediated by estrogen.  As high fiber diets continue 
to be endorsed by the leading dietary and public health associations, a better understanding of 
the direct and indirect effects of fiber intake on lipoprotein cholesterol levels is essential.  
This knowledge could provide further insight regarding possible mechanisms, as well as 
valuable knowledge for the interpretation of studies of fiber intake among women of 
reproductive age.   
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 This dissertation uses extant data from 259 regularly menstruating women enrolled in 
the BioCycle study, a prospective study of menstrual cycle function to address the following 
specific aims: 
1. Evaluate the association between serum estrogen and short-term changes in 
lipoprotein cholesterol levels during the normal menstrual cycle. 
2. Evaluate the association between serum lipoprotein cholesterol levels and risk of 
incident anovulation during the normal menstrual cycle. 
3. Determine the controlled direct effect of dietary fiber intake on lipoprotein 
cholesterol levels not mediated by estrogen. 
II.  BACKGROUND 
A. Menstrual Cycle Function 
1. Reproductive Physiology 
 The menstrual cycle is a complex process involving multiple hormones which are 
regulated by intricate feedback mechanisms.12, 29  Hormones, such as LH, FSH, estrogen, and 
progesterone follow a cyclical pattern which is coordinated by the hypothalamic-pituitary-
ovarian axis.  Typically, the cycle is divided into two distinct phases: follicular and luteal.  
The cycle begins with menstrual bleeding, and is then followed by the follicular phase.  At 
the beginning of the follicular phase estrogen and progesterone levels are low, and FSH 
levels start to increase.  Towards the end of the follicular phase estrogen levels begin to rise.  
Ovulation is stimulated by a surge in LH and FSH, and marks the end of the follicular phase 
and the beginning of the luteal phase.  Estrogen levels also peak around this time, and 
progesterone levels start to increase.  During the luteal phase, LH and FSH levels drop, and 
progesterone levels increase and remain high.  In addition, estrogen levels are high during the 
luteal phase.  If the egg is not fertilized, then both progesterone and estrogen levels drop and 
the cycle begins again.  Figure 2.1displays the normal hormonal pattern during the menstrual 
cycle not resulting in conception.30  Despite the consistent patterns that exist, there is 
considerable variation in “normal” menstrual cycle characteristics both within and between 
women.   
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2. Menstrual Diary Studies 
 Much of the data available regarding menstrual cycle characteristics comes from four 
seminal menstrual diary studies.  These include the Matsumoto study of 701 Japanese women 
aged 13 to 52 who were followed for 2 years,31 the Treloar study of 2700 white American 
women aged 10 to 56 who were followed for up to 29 years,32 the Chiazze study of 2316 
American and Canadian women aged 15 to 44 followed for two years,33 and the Vollman 
study of 691 Swiss women aged 11 to 58 who were followed for one to 39 years.34  The 
World Health Organization (WHO) also conducted a series of short menstrual diary studies, 
and several smaller studies have been conducted in specific populations across the world.   
 
3. Menstrual Cycle Characteristics 
Because hormone levels are usually difficult and expensive to monitor, menstrual 
cycle function is typically characterized by menstrual cycle length, phase length, absence of 
ovulation, or age at menarche.35  Less information is available on bleed duration and amount 
of flow.  Menstrual disorders can be broadly placed into four categories: disruptions in 
bleeding patterns, ovarian function, and pain.  Disruptions in bleeding patterns include 
menorraghia (heavy or prolonged bleeding), oligomenorrhea (infrequent menstruation), 
polymenorrhea (frequent menstruation), or amenorrhea (cessation of menses).  Two measures 
of ovarian function are anovulation and luteal phase deficiency, which are commonly defined 
as progesterone levels that do not reach 5 ng/mL for at least 5 days.36  Ovarian dysfunction 
may or may not result in altered bleeding patterns.  Pain (dysmenorrhea) or other 
symptomatology (premenstrual syndrome) are also common menstrual disorders. 
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4. Cycle Length Variability 
 Menstrual cycle length is highly variable both between women and within a woman.  
Variability in cycle length tends to be greatest after menarche and shortly before 
menopause.35  Women ages 20 to 40 tend to experience less variability in their cycle length, 
but cycle length over this time tends to shorten from 30.1 to 27.3 days (Figure 2.2).32  It has 
been argued that the classic studies provide a limited understanding of cycle length 
variability because they assume that cycle length follows a normal distribution.35 
 In the Agricultural Health Study, the prevalence of short cycles was estimated to be 
about 9.7%, of long cycles 3.2%, of irregular cycles 5%, with 13.3% of women experiencing 
intermenstrual bleeding or spotting.37 The prevalence would be assumed to vary in other 
populations. 
 Age is a major factor in determining menstrual cycle variability.  Absolute weight and 
change in weight has been shown to influence menstrual function.  This could be due to 
nutritional factors, or due to the effect of body fat on endocrine function.  Fat tissue is a 
reservoir for steroid hormones and a site of estrogen production and could therefore directly 
influence endocrine function. 
 
5. Cycle Phase Length Variability 
 There is very little data available on lengths of the follicular and luteal phases.  They 
are difficult to measure because they require valid and accurate detection of the timing of 
ovulation.  Ovulation may be classified differently based on whether the study used 
ultrasound, basal body temperature timing methods, or daily urine samples.  Detection could 
also depend on the number of blood or urine samples collected and when they were collected.  
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With these limitations in mind, one study that evaluated phase lengths found that when long 
cycles were excluded, the follicular phase varied from 10 to 23 days, with a mean length of 
13 to 15 days.  The luteal phase was observed to vary from 8 to 17 days, with a mean of 12 to 
14 days.  When long cycles were included, the follicular phase was estimated to be longer 
with a mean of 17 to 18 days.38  It was also observed that the length of the follicular phase 
tended to decrease with age from about 14 days at ages 18 to 24 to 10.5 days at ages 45 to 60 
among women still menstruating.  Data from Vollman and Lenton suggest that once 
reproductive maturity is attained, the luteal phase remains relatively constant until 
menopause.34  
 
6. Cycle Length and Health Outcomes 
Menstrual cycle characteristics have been associated with various reproductive 
outcomes, such as fertility, and spontaneous abortion.39  In addition, certain cycle 
characteristics have been associated with breast40-45 and ovarian cancer46, 47, uterine 
fibroids,48 diabetes,49 and cardiovascular disease.50, 51  Menstrual irregularities have also been 
suggested to be associated with metabolic and hormonal abnormalities.   
 Long and irregular cycles have been associated with menarche after age 14, with 
depression, and with increasing body mass index (BMI).37, 50  Length of the cycle has also 
been found to increase with increased parity, and decreased age, non-White race, and current 
smoking status.52 The likelihood of irregular cycles also tends to increase with age, BMI, and 
number of cigarettes smoked per day.52   
 Long menstrual cycles have been associated with anovulatory cycles.35  In fact, short 
and long cycles are 10 to 30% more likely to be anovulatory than cycles of 25 to 35 days.  It 
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is estimated that for women aged 10 to 14 that approximately 50 to 60% of cycles are 
anovulatory, and for women aged 25 to 39 that approximately 2 to 7% of cycles are 
anovulatory, whereas, women above 50 years of age have approximately 34% anovulatory 
cycles.  It has been hypothesized that this age-related change in incidence of anovulatory 
cycles is directly associated with changes in variability of menstrual cycle length throughout 
a woman’s reproductive life.  
 Menstrual cycle characteristics have also been associated with fertility and 
spontaneous abortion.  Shorter cycles were less likely to be followed by conception, and 
likely reflect a shortened follicular phase.39  Cycles with lengths of 30 to 31 days preceded 
cycles with the highest fecundity.  Conceptions after shorter or longer cycles were more 
likely to be spontaneously aborted as compared to 30 to 31 day cycles.  
 It is important to note that oral contraceptives (OCs) are often prescribed for 
menstrual irregularities.  Therefore, studies of normally menstruating women which exclude 
OC users probably underestimate the prevalence of long and irregular cycles among all 
reproductive-aged women.37 
 
7. Validity of Self-Reported Menstrual Cycle Length 
 Validity of self-reported cycle length was examined in a recent study by Small et 
al.39.  This study observed that 43% of women reported their cycle length to be more than 2 
days different from their actual mean length.  When categorized into short (<26), normal (26 
to 35), or long (>35) cycles, 21% were misclassified.  Accuracy of reporting was associated 
with older age, marriage, and higher income.  Women with short and long cycles were less 
likely to report accurately, and as cycle variability increased the ability of a woman to 
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accurately report her cycle length also decreased.  Another recent study by Jukic et al. found 
that on average, women overestimated their cycle length by 0.7 days.53  Systematic 
differences in reporting were found to be associated with sexual activity, history of infertility, 
parity, BMI, exercise, and prior treatment for irregular cycles.53 
 
B. Lipid Metabolism 
1. Lipoprotein Structure and Function 
Cholesterol is found in all tissues, and is required for the building and maintenance of 
cell membranes.  Cholesterol is either derived from the diet through animal fats or 
synthesized in the endoplasmic reticulum.  Transport in the blood is achieved through 
lipoproteins, specifically chylomicrons, intermediate density lipoproteins (IDL), VLDL, 
LDL, and HDL.  Lipoproteins contain a core of neutral lipids, triglycerides, and cholesteryl 
esters, and an outer shell of more polar phospholipids, free cholesterol, and proteins.  
Apoproteins coat the surface of lipoproteins and function as lipid solubilizers, metabolic 
recognition sites, and coenzymes for catabolic enzymes.  Lipoproteins all have the same 
basic structure, but differ in their relative contents of cholesterol, triglycerides, 
phospholipids, and apoproteins.10  Chylomicrons, VLDL, and LDL all transport cholesterol 
to peripheral tissues in the body, whereas HDL works to remove cholesterol through 
transport of cholesterol back to the liver.  HDL metabolism is also known as reverse 
cholesterol transport.  HDL is the smallest and densest of the lipoproteins and high levels 
have been associated with a lower risk of cardiovascular disease.  High levels of LDL and 
total cholesterol on the other hand have been associated with an increased risk of 
cardiovascular disease.  In general, individuals with a less atherogenic plasma lipid profile 
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are at lower risk for coronary heart disease.  An atherogenic profile is one that is associated 
with higher levels of total cholesterol and LDL cholesterol, and lower levels of HDL 
cholesterol.   
HDL functions to return cholesterol to the liver and to steroidogenic organs such as 
the adrenals, ovaries, and testes.  HDL is removed using both direct pathways involving HDL 
receptors such as scavenger receptor BI and an indirect pathway mediated by cholesteryl 
ester transfer protein.  This protein exchanges triglycerides of VLDL and cholesteryl esters of 
HDL.  This exchange results in converting VLDL to LDL, which is subsequently removed by 
LDL receptors, and the breaking down of unstable triglycerides in HDL by hepatic lipase.  
These HDL particles are then available for uptake from the cells.     
 
2. Role of Steroid Sex Hormones in Lipoprotein Metabolism 
There is considerable evidence that women have an increased level of lipoprotein 
transport as compared to men. Much of this difference is attributed to sex hormones.  In 
general, estrogens have been found to have favorable effects on lipoprotein metabolism by 
lowering LDL and increasing HDL.9-11  Progestins, on the other hand, have been associated 
with unfavorable effects on lipoprotein metabolism by increasing LDL levels and decreasing 
HDL. These differences have been attributed to estrogen’s impact on increasing VLDL 
synthesis and inhibiting hepatic lipase and lipoprotein lipase activity.  Estrogen works to 
stimulate hepatic lipid production, as well as the formation of other proteins in the liver.  
Androgens, however, oppose all of the stimulatory effects of estrogen on protein synthesis.  
Estrogens also play a major role in VLDL production in women.  Uptake and esterification of 
triglycerides and VLDL secretion have been shown to be increased in women,9 without a 
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subsequent increase in plasma levels, suggesting that rates of VLDL transport and removal 
are greater in women.  Most LDL are formed from VLDL and VLDL remnants.  With the 
stimulatory effects of estrogen on VLDL production, a similar increase in LDL and HDL 
would be expected.  However, estrogen also directly affects the upregulation of the LDL 
receptors, thereby increasing the rate of LDL removal.  Again, androgens have the opposite 
effect by downregulating the activity of the LDL receptor.  Reductions in hepatic lipase 
activity due to estrogen have the effect of decreasing triglyceride removal from HDL, and 
HDL levels are typically higher among women than men.9  Since women have a greater rate 
of lipoprotein transport, it is thought that the effects of diabetes or obesity would lead to a 
greater increase in plasma lipoproteins in women when compared to men.  In fact, those 
effects are observed when comparing lipoprotein levels in diabetic men and women with 
levels in normal men and women.9  This also helps in understanding why diabetes is a more 
significant risk factor for coronary heart disease in women. 
 
3. Differences in Lipid Levels by Age, Sex 
Lipid profiles have been shown to differ between men and women throughout life.  
Interestingly, cholesterol levels tend to be higher among girls than among boys at birth, but 
this switches during the reproductive years.  HDL cholesterol levels are also higher in 
women than in men at all ages.  This has been used to explain the fact that women of 
reproductive age are at decreased risk for heart disease as compared to men.  LDL levels rise 
with age in both men and women, and after 55 may be higher in women than in men.10  HDL 
declines slightly in women after 55 (corresponding to postmenopausal lowering of estrogen 
levels).   
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4. Hormone Replacement Therapy 
The role of exogenous hormones on lipid metabolism has been well studied.  The 
largest trial was conducted by the WHI, and investigated the hormone replacement therapy of 
estrogen plus progestin.11  In the WHI trial, postmenopausal women who received the 
estrogen plus progestin therapy showed an improved lipid profile, but no beneficial effect on 
heart disease.6  Specifically, women randomly assigned to estrogen plus progestin had greater 
reductions in total cholesterol, LDL, glucose, and insulin levels, and greater increases in 
HDL and triglycerides, than those on placebo.  Women with higher baseline LDL levels 
appeared to have a greater excess risk of coronary heart disease with hormone therapy.  WHI 
concluded that estrogen plus progestin hormone replacement therapy does not confer cardiac 
protection and may in fact increase the risk of coronary heart disease.  In general, studies 
evaluating the impact of hormone replacement therapy on lipid metabolism have found that 
estrogen therapy reduces plasma LDL levels, and increases HDL and triglyceride levels.  
Addition of a progestin tends to attenuate some of the lipid benefits of estrogen, in particular, 
the increase in HDL levels.54 
 
5. Oral Contraceptives 
Studies of the effect of OC’s on lipoprotein metabolism yield similar results to that of 
hormone replacement therapy.  Estrogens are again in general associated with lower LDL 
levels and higher HDL levels, and progestins are associated with higher LDL and lower HDL 
levels.  Estrogen-rich OC’s have also been found be associated with increased triglyceride 
levels,54, 55 but those containing both estrogens and progestins typically did not have the same 
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effect.  A recent study found that two low dose monophasic OC’s containing ethinyl estradiol 
30 mcg and either chlormadinone acetate 2 mg or 0.15 mg desogestrel had similar effects on 
lipoprotein levels (increased triglycerides, HDL, and decreased LDL and LDL/HDL ratio), 
although total cholesterol levels remained unchanged.56  On the other hand, a different study 
found no beneficial effects of low-dose OC’s containing 30mcg ethinyl estradiol and 150 
mcg levonorgestrel on HDL levels.57  Interestingly, in a study comparing OC users, nonusers, 
and levonorgestrel-releasing intrauterine device users, intrauterine device users displayed 
lower HDL and total cholesterol levels compared with the nonusers, whereas OC users had 
raised lipid levels (total cholesterol and triglycerides).58 The variable effects of OC’s on lipid 
metabolism are influenced by several factors.  The dose and type of OC’s appears to make a 
difference in the changes in levels of plasma lipoproteins observed.  In addition, studies 
differ by the age of the women studied, smoking, exercise, diet, alcohol, treatment for other 
conditions, and specific sampling procedures.  Interestingly, the effects on lipid metabolism 
do not seem to be progressive with continued treatment, but rather go back to pretreatment 
concentrations after discontinuation.59 
 
6. Lipids and Menstrual Cycle Function 
The effects of exogenous hormones on lipid metabolism, and the differences observed 
in lipoprotein transport between men and women all lend evidence to support that 
endogenous female sex hormones play a significant role in lipoprotein metabolism.  The 
effect of endogenous hormones on lipoprotein metabolism is not well understood however, 
and not all studies have observed cyclic changes in lipoprotein levels across the menstrual 
cycle as would be expected.  Some studies have shown that plasma lipid levels fluctuate 
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during the menstrual cycle,60-75 while others have not observed these changes.76-83  Within 
studies, it is also common to find that only certain measures of cholesterol (total, HDL, or 
LDL) differ between cycle phases.  The contradictory results could be due to a number of 
possible factors.  The changes in lipids between different days of the menstrual cycle are 
fairly small in magnitude.  Studies with small sample sizes are then underpowered to detect 
these small effects.  Inappropriate timing of sample collection to menstrual cycle phase could 
further mask the effects and complicate the results of these studies.  Studies looking at 
differences in LDL often fail to account for the fact that LDL is not directly measured, but is 
in fact indirectly calculated using the Friedewald formula.84  In addition, analytical methods 
that appropriately account for intra-individual variability are rarely applied.85  
  Total cholesterol and LDL are often found to be lower during the luteal phase of the 
menstrual cycle, as compared to the follicular phase.  The luteal phase corresponds to the 
time of the cycle when estradiol and progesterone levels are high.  Studies of this relationship 
have typically consisted of comparisons across only one cycle, with few measurements 
throughout the cycle. Timing of cholesterol measurements to menstrual cycle phase was 
made by determining hormone levels either by basal body temperature methods 67, 80, 
ovulation charts,63 or blood samples.63, 67, 68, 70, 73-75, 77, 78, 80, 86  None of the past studies have 
utilized a fertility monitor to time ovulation during the cycle.  Of the studies where blood 
samples were used, the sampling periods varied from 174 to 268 times per week, to every 5th 
day,63, 63 to once per cycle phase73, 80, 86 as determined by menstrual cycle length, or up to 3 
consecutive samples per phase.77  Analysis of these studies also was usually limited to paired 
t-tests, repeated measures analysis of variance (ANOVA), or correlation analyses, which 
were only able to compare mean cholesterol levels between the follicular and luteal phases of 
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the menstrual cycle.  Sample sizes were typically very small.  In fact, only three studies64, 86, 
87
 have been completed that included more than 50 participants.  Of the three studies with 
more than 50 participants,64, 86, 87 one compared cholesterol levels between the follicular and 
luteal phases (n=54),86 one was cross-sectional and only studied the mid-follicular phase 
(n=177),87 and one consisted of daily salivary ovarian steroid concentrations (n=206).64   The 
largest study by Furberg et al. consisted of multiple hormone measurements, but only one 
lipid measurement taken at the beginning of the menstrual cycle.64  Proper timing of blood 
sampling for multiple cycles, along with multiple hormone and lipid measurements across 
the cycle would help to further elucidate the temporal variability in lipid levels. 
Three studies used mixed modeling techniques to better understand variability in lipid 
levels across the cycle and to appropriately account for within-woman variability.74, 77, 88 
These studies used modeling techniques similar to what will be utilized for the proposed 
analysis and therefore will be discussed in more detail.  These studies were limited by very 
small sample sizes and uncertain timing of menstrual cycle phase.  Wall et al. 88 studied 12 
women for one cycle, and found significant changes across the cycle.  The strength of this 
study was the fact that they collected 20 blood samples throughout a single menstrual cycle.  
These samples were then divided into 6 phases and averaged within each phase.  Even 
though daily blood samples were collected, there were no repeat measurements available 
from a second cycle, and daily measurements were averaged into 6 groups for the multi-level 
analysis.  A study by Reed et al.74 compared intra-individual differences in lipid levels across 
the cycle among 39 premenopausal women enrolled in the Dietary Effects on Lipoproteins 
and Thrombogenic Activity (DELTA) Study.  Blood samples were taken once per week for 
the last 4 weeks of each 8 week diet period for 3 non-consecutive cycles.  Menstrual cycle 
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phase was determined based on the weekly hormone measurement and a personal menstrual 
calendar.  The intra-individual variability among the premenopausal women was compared to 
the variability in 18 postmenopausal women, and 36 men under strict dietary conditions.  
They found that lipid levels followed a cyclical pattern for premenopausal women, but that 
the same patterns did not exist for men or postmenopausal women.  However, the authors 
emphasized that the cycling only represents a small fraction of the total biologic variability, 
and that the intra-individual variability is so similar to that of postmenopausal women and 
men that timing of cholesterol measurements for premenopausal women is unnecessary.  
Again this study was very small, and appropriate classification of measurements to menstrual 
cycle phase was not precise.  No adjustment was made for analytical variability, and because 
they were testing the effects of 3 different diets, between-diet variability in lipids is 
inherently included in their analysis.  In their analysis of lipid levels, they did not control for 
diet. 
It is evident that there are several common limitations in the current literature. Sample 
collection needs to occur at appropriate times during the menstrual cycle, and measurement 
of both hormone levels and lipid levels at various points would be ideal.  Measurement 
during the follicular and luteal phases, as well as during menstruation and ovulation are 
necessary to characterize the entire cycle.  These design issues need to be employed in a 
large sample, with follow-up for more than one cycle.  Appropriate statistical analysis will 
also help to elucidate this relationship.  
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C. Synthesis of Steroid Hormones 
Cholesterol is the initial precursor for steroid biosynthesis and plays a central role in 
the synthesis of sex hormones such as progesterone, estrogen, and testosterone.  Cholesterol 
is synthesized into steroid hormones from cholesterol that has been synthesized de novo, that 
has been acquired from the plasma, or that has been stored as esters.   
 
1. Basic Hormone Structure 
Steroid hormones are derived from cholesterol and are lipids that share a common 
nucleus comprised of 17 carbon atoms.  Naturally occurring steroid hormones are named 
according to the structures of the parent compound which are differentiated by subtle 
modifications of the four fused rings of the sterol skeleton and side chain.  In particular, 
cholestanes are made up of 17 carbons (e.g. cholesterol), pregnanes of 21 carbons (e.g. 
progesterone), androstanes of 19 carbons (e.g. testosterone), and estranges of 18 carbons (e.g. 
estradiol).12  Systemic names not only designate the parent structure, but also the number, 
location, and orientation of substituents attached to the central ring.  Figure 2.3 shows the 
chemical structure of various steroid hormones.  It is readily apparent that they share a 
common parent structure. 
 
2. Steroid Hormone Production 
 Estrogen is primarily produced by developing follicles in the ovary and the corpus 
luteum, and is stimulated by FSH and LH.  Estrogens are also produced in other tissues, but 
in smaller amounts.  The synthesis of estrogens begins in the theca interna cells of the ovary 
and involves a series of sequential modifications of cholesterol.  The first step in the 
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synthesis of ovarian hormones is the conversion of cholesterol to pregnenolone (Figure 2.4).  
Pregnenolone can then be converted to progesterone.  Further metabolism results in synthesis 
of testosterone, aldosterone, and cortisol, and subsequently into estrogens.  Both 
androstenedione and testosterone are substrates for estrogen production.  Figure 2.4  shows 
the sequence of steroidogenesis, the process of generating various forms of steroid hormones 
by the transformation of other steroids, starting with the conversion of cholesterol. 
Depending on the conversion process, there are three different naturally occurring 
types of estrogens that could be produced, including estradiol, estrone, and estriol.  Estradiol 
is the primary estrogen present among premenopausal women, and estrone the primary 
estrogen present among postmenopausal women.  Estradiol is secreted directly from the 
ovary and estrone is primarily derived from conversion of estradiol or androstenedione.  
Estrone can be further metabolized to estriol.  The synthesis of androstenedione from 
cholesterol takes places in the theca interna cells in the ovary, and results in the formation of 
estrone or estradiol, either immediately or through testosterone.  The structure of each type of 
estrogen is shown in Figure 2.5. 
 
3. Role of Lipoproteins in Hormone Synthesis 
Lipoproteins function to carry cholesterol to tissues for hormone synthesis.  LDL is 
the primary way that cholesterol reaches the endocrine glands to be used for steroid hormone 
formation.  Ovarian cells contain LDL receptors, which function to release cholesterol to be 
utilized for steroid biosynthesis.  Once transported to steroidogenic organs by lipoproteins, 
cholesterol can then be synthesized into the steroid hormones.   
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D. Dietary Fiber  
1. Health Benefits of Dietary Fiber Intake 
 Increased fiber intakes are recommended due to the many health promoting benefits 
associated with fiber consumption.  In fact, diets high in fiber have been associated with 
reduced risk of various chronic diseases such as cardiovascular disease,89, 90 diabetes,91 and 
breast cancer.92-95  In addition, fiber has been shown to lower cholesterol and lipoprotein 
levels,15 control weight 96, reduce constipation,97 reduce blood pressure,98 and help control 
blood sugar levels.99, 100   
 High fiber intakes have also been shown to be associated with lower levels of 
estrogen.20-27  It has been hypothesized that the effects of fiber on the development of breast 
cancer are potentially mediated by changes in estrogen levels.101  It is not well understood 
how much of the observed effect of fiber on cholesterol and lipoprotein levels is mediated by 
changes in estrogen. 
 
2. Sources and Types of Fiber 
 Dietary fiber is the collective term for the carbohydrate substances found in plants 
that are indigestible by human enzymes.  Dietary fiber is found in foods such as whole grain 
products, fruits, vegetables, and legumes.  Sources of dietary fiber are often divided into 
soluble and insoluble components, based on whether or not they are water soluble.   Soluble 
fiber is found in all plant foods, but in varying quantities.  Sources of soluble fiber include 
legumes, oats, rye, barley, fruits such as plums and berries, vegetables such as broccoli, 
carrots, potatoes, sweet potatoes, onions, and psyllium seed husk.  Sources of insoluble fiber 
include whole grain foods, bran, nuts, seeds, vegetables such as green beans, cauliflower, 
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zucchini, celery, and tomato skins.  It was assumed that classifying fibers by their solubility 
would help to distinguish between their biological responses.  However, the physiological 
response to sources of fiber is affected by more than solubility, but also by factors such as 
fermentability, viscosity, and bile acid binding ability.102  Because of these additional factors, 
the Institute of Medicine (IOM) has recommended new definitions for dietary fiber.103  
Specifically, the new terms recommended for describing fiber intake are dietary fiber and 
functional fiber.  The term dietary fiber is used to describe the nondigestible carbohydrates 
and lignin that are intrinsic and intact in plants, which is to be distinguished from functional 
fiber which consists of the isolated nondigestible carbohydrates that have beneficial 
physiological effects. 
 
3. Recommended Intake 
Current recommendations for fiber intake are 25 g per day for adult women ages 19 
to 50 and 38 g for adult men ages 19 to 50.104  These recommendations from the IOM are 
based on epidemiologic evidence showing a protective effect of lipids on cardiovascular 
disease.105  It should also be noted that for fiber intake, only an “Adequate Intake (AI)” was 
established.  Since fiber is not absorbed, blood fiber levels cannot be measured, and a 
Recommended Dietary Allowance (RDA) could not be calculated.  The AI was based on the 
median fiber intake that was observed to have the lowest risk of coronary heart disease.  The 
usual intake of dietary fiber in the United States is far below the recommended amount with 
an average of only 15 g/day.103 
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4. Effect of Fiber on Estrogen Levels 
Increased consumption of dietary fiber has been associated with decreased levels of 
estrogen in several observational studies and randomized controlled trials.20-27  These studies 
were completed in various study populations, with varying levels of fiber consumption 
(mostly very high amounts of fiber intake), and usually with only a few measurements during 
the menstrual cycle.  The most comprehensive study to date was done by Bagga et al. in 
which 12 women on a high fiber diet were followed for 2 menstrual cycles with serum was 
collected every other day.20 This study found 18% and 26% reductions in estradiol in the 
follicular and luteal phases, respectively, but no significant changes for other reproductive 
hormones.  The most recent study followed 44 women for one menstrual cycle and evaluated 
daily estrogen levels in urine, as well as serum levels during the follicular phase.25  This 
study found a reduction in serum estrogen levels of 15% associated with high fiber/low fat 
diets, as well as reductions in the daily urine measurements of estrogen.  The largest 
randomized controlled trial followed 213 women for one year and found a reduction of 7.5% 
in levels of estrogen among women on a high fiber diet, based on only one collected serum 
measurement per cycle.21  While these studies each have their own limitations, the evidence 
points towards an association between increased fiber consumption and reduced estrogen 
levels.   
Dietary fiber intake is hypothesized to reduce levels of circulating estrogen through 
inhibiting deconjugation and reabsorption of estrogen from the colon.25  Additionally, all 
biliary estrogens are conjugated and have to be hydrolyzed before absorption.106  An increase 
in β-glucuronidase activity in feces associated with a high fat and low fiber diet leads to 
increased reabsorption of estrogen.106, 107 The other proposed mechanism by which dietary 
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fiber intake reduces estrogen levels is through the elimination of estrogens by the fecal route 
because fiber binds estrogens,108 and works to speed up intestinal transit.109 
 
5. Effect of Fiber on Estrogen Levels in the BioCycle Study 
The effect of fiber on estrogen levels was also evaluated in the BioCycle study.  It 
was observed that increased consumption of dietary fiber was associated with decreased 
levels of estrogen as well as an increased risk of incident anovulation.  These results 
remained consistent whether fiber intake was considered as a continuous variable, or 
categorized according to the AI.  Dietary fiber consumption was inversely associated with all 
peak hormone concentrations (estrogen, progesterone, LH, FSH) (P<0.05), and with an 
increased risk of anovulation using random effects models adjusted for total calories, age, 
race, and vitamin E intake. Body mass index (BMI) was not found to be confounder in this 
study.  Each 5 g/day increment in total fiber intake was associated with a 2.04 fold increased 
risk (95% confidence interval (CI) 1.26-3.28). Corresponding adjusted odds ratios (aORs) 
and (95%CI) for fruit and grain fiber were 7.98 (1.94-32.9) and 3.58 (1.50-8.52), 
respectively. Although the confidence intervals were wide, we found a greater risk of 
anovulation among women with fiber intakes at or above the AI (25 g/day) compared to 
those consuming less than 10 g/day (aOR=26.4, 95%CI 2.9-240.5). 
 
6. Lifestyle Measures to Reduce Cholesterol 
Several factors are associated with high cholesterol levels, such as obesity, physical 
inactivity, smoking, alcohol consumption, high-carbohydrate diets, diseases such as type 2 
diabetes mellitus, chronic renal failure, and genetic predisposition.110, 111  Several lifestyle 
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changes can be made in order to manage lipid levels.  In particular, increased weight is a 
determinant of low HDL levels, and weight loss has positive effects on HDL cholesterol.110  
Diet and exercise are two primary ways of lowering cholesterol, which can be used in 
addition to lipid-lowering medications for individuals who require prescription treatment.  It 
is recommended that individuals avoid saturated fats, and include sources of soluble fiber in 
their diet.112, 113  It has also been recommended that eating one-half cup of bran cereal that 
contains 5 g of soluble fiber could lower LDL levels by 5%, or one handful of almonds (70 
g) could decrease LDL by 8%.  Response to changes in diet vary considerably, but it can be 
expected that the adoption of a diet low in saturated fat will result in about a 8 to 10% change 
in cholesterol levels, and an additional lowering of 3 to 5% if dietary cholesterol is also 
reduced.110  Weight management and physical activity are also recommended to control 
cholesterol levels.  Studies of the effects of physical activity have shown lower triglyceride 
levels (mean decreases of 24% for regular exercise) associated with exercise training.110  
Total cholesterol and LDL cholesterol do not show changes associated with exercise, but are 
lowered due to changes in body weight, body fat, and dietary fat that usually accompany 
physical activity. 
 
7. Effect of Fiber on Lipid Metabolism 
 Diets high in fiber have been shown to have an impact on serum cholesterol and 
lipoprotein levels.14  In fact, decreases of up to 20% in serum cholesterol have been observed 
with high fiber diets.16, 17  The decrease is usually due to the reduction in LDL cholesterol.  
HDL and triglyceride levels do not typically show the same effect. 
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 The mechanisms involved in the reduction of serum cholesterol levels due to 
increased fiber intake remain somewhat inconclusive.  Potential mechanisms are displayed in 
Figure 2.6.  Diets high in fiber could potentially be displacing foods that are high in saturated 
fat, and indirectly work to lower lipid levels.  Another potential mechanism is through bile 
acid metabolism.  Specifically, serum cholesterol levels are thought to decrease due to 
viscous polysaccharides acting in the gastrointestinal tract by decreasing cholesterol and fatty 
acid absorption, and by decreasing absorption of biliary cholesterol or bile acids.102  In this 
way, bile acid synthesis increases, and fecal excretion of bile acids is increased.  One study in 
particular measured bile acid kinetics to test this hypothesis and observed that oat bran 
consumption lowered serum cholesterol in part by altering bile acid metabolism, and in part 
by decreasing the synthesis of cholesterol.114  Animal models have also shown that the water-
soluble fiber most prevalent in oats and barley is the active agent causing the altered 
cholesterol metabolism.102  Although the mechanism is not fully understood, the evidence 
points to small increases in the fecal excretion of bile acids and neutral steroids that is not 
fully accounted for by de novo cholesterol synthesis.111  It has also been hypothesized that 
fiber may act through altered serum hormone concentrations or short-chain fatty acids that 
affect lipid metabolism.    
 
E. Summary of Research Gaps 
The purpose of this dissertation is to understand how the menstrual cycle interacts 
with other metabolic processes, specifically lipid metabolism.  In particular we are interested 
in the effects of estrogen on lipid metabolism, the effects of baseline lipoprotein cholesterol 
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levels on the risk of incident anovulation, and the direct effects of dietary fiber intake on 
lipoprotein cholesterol not mediated by estrogen.   
It is not well established whether lipoprotein levels fluctuate during the menstrual 
cycle, and whether estrogen is associated with lipoprotein cholesterol levels.  Previous 
studies have been limited by several factors (small sample sizes, follow-up for a single cycle, 
few measurements during the cycle, single comparison between follicular and luteal phases, 
and differences in markers of ovulation to time lipid and hormone measurements).  Further, 
the effect of lipoprotein cholesterol levels on risk of incident anovulation has not been 
evaluated prospectively in a group of regularly menstruating women.  Although the effect of 
fiber on lipoproteins is fairly well established, menstrual cycle phase is generally not taken 
into account.  It is unclear how much of the effect of fiber on lipoprotein cholesterol levels is 
mediated by the effect of fiber on estrogen.   
This study seeks to improve upon limitations of previous studies in order to quantify 
and understand the variability and cyclical nature of both hormones and lipoprotein 
cholesterol levels during the normal menstrual cycle.  The BioCycle study is a unique data 
source and is especially appropriate for addressing the questions of interest because of the 
quantity and quality of the data collected.  Not only are biomarkers available, but various 
questionnaires regarding lifestyle and demographic factors were also administered.  
Biomarkers were measured in serum from 259 women at 16 time points across two menstrual 
cycles, and lifestyle questionnaires were also administered at multiple points during the 
study.  This study also has the advantage of well-timed study visits because of the use of 
fertility monitors to track hormone levels throughout the cycle.  Using this new technology, 
menstrual cycle phases were defined more accurately, representing a significant 
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improvement over previous studies.  No previous study has had such a large sample and both 
hormone and lipoprotein cholesterol measurements at multiple time points.  Basic descriptive 
analysis will be completed, along with the use of random effects models to account for both 
intra- and inter-individual variability.  The longitudinal nature of the data allows us to also 
use mixed modeling techniques to better understand variability across the cycle and to 
appropriately account for within-woman variability.  Marginal structural models also will be 
used to adequately account for time-dependent confounding due to changing hormone levels 
throughout the cycle. 
This study adds a significant contribution to the literature because of the design, data 
quality, and improvements over previous studies.  Understanding variations in lipoprotein 
cholesterol levels is important because there may be clinical implications regarding the 
appropriate timing of measurement during the cycle, as well as implications on the design 
and interpretation of studies in women of reproductive age.  Further information regarding 
the effect of endogenous estrogen on lipoprotein metabolism may also help elucidate 
estrogen’s role in protection against atherosclerosis.  This is also the first study to our 
knowledge to prospectively identify endocrine markers of sporadic anovulation in a group of 
regularly menstruating women.  Understanding the factors associated with anovulation is 
important as anovulation might be associated with delayed time to pregnancy.  
Understanding the direct effects of dietary fiber intake on lipoprotein cholesterol levels, not 
mediated by estrogen, could provide further insight regarding possible mechanisms, as well 
as valuable knowledge for the interpretation of studies of fiber intake among women of 
reproductive age.    
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F. Tables and Figures 
Figure 2.1. Pattern and timing of hormonal changes during the normal menstrual cycle.30 
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Figure 2.2.  Median menstrual cycle lengths from menarche to menopause. 12 
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Figure 2.3.  Chemical structure of cholesterol and various steroid hormones. 
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Figure 2.4.  Structure of cholesterol. 
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Figure 2.5.  Structure of three naturally occurring types of estrogen. 
 
33 
 
Figure 2.6.  Potential mechanisms for the effect of fiber on lipid metabolism. 111 
 
 
 
 
 
 
III. SPECIFIC AIMS  
 This dissertation uses extant data from 259 regularly menstruating women enrolled in 
the BioCycle study, a prospective study of menstrual cycle function to address the following 
specific aims: 
1. Evaluate the association between serum estrogen and short-term changes in 
lipoprotein cholesterol levels during the normal menstrual cycle. 
2. Evaluate the association between serum lipoprotein cholesterol levels and risk of 
incident anovulation during the normal menstrual cycle. 
3. Determine the controlled direct effect of dietary fiber intake on lipoprotein 
cholesterol levels not mediated by estrogen.  
 
IV. METHODS 
A. Study Design 
The BioCycle study was designed to enroll 250 participants for 2 menstrual cycles, 
and to collect biologic samples, conduct physical measurements and administer 
questionnaires across two complete menstrual cycles among these women. In order to test the 
feasibility of the study and its measures, a pilot study of 9 subjects was conducted for 1 cycle 
prior to finalizing the study protocol. The full study involved biospecimen collection (blood 
and urine) at 8 key times per cycle for 2 cycles per participant. The collection times were 
selected to include points in the menstrual cycle with the most hormonal variation and 
include menstruation, the middle of the follicular phase, the estrogen peak, the LH and FSH 
surge, ovulation, progesterone elevation and peak, and immediately before menstruation.  
Based on an approximate 28-day cycle length, these would represent approximately days 2, 
7, 12, 13, 14, 18, 22, and 27.   
Figure 4.1 describes the expected hormonal variation occurring at each specific time 
during the cycle. Fertility monitors (Clear Blue TM) were used to assist in the timing of 
specimen collection, and have been shown to improve timing of clinic visits.  The strengths 
of these methods will be described in Section C. Cycle visits were routinely scheduled 
between 7:00 am and 8:30 am to allow for collection of fasting samples and to reduce diurnal 
variation.  A complete hormonal profile and lipid profile were measured in serum collected at 
each clinic visit.  Participants were also asked to complete questionnaires on the following 
topics: life style; health history; skin and body hair patterns; physical activity (IPAQ – The 
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International Physical Activity Questionnaire); family medical history questionnaire; 
Perceived Stress Scale (14 items); Depression Scale (Center for Epidemiologic Studies 
Depression Scale, CES-D); and occupational history. Nutrient data were collected using a 24 
hour recall from the University of Minnesota database.  Details regarding assessment of 
hormones, lipoproteins, and other covariates are described in each of the Dissertation 
Manuscript chapters. 
 
B. Study Population 
Healthy, normally menstruating, premenopausal women ages 18 to 44 were recruited 
from clinical practices in western New York.  Specifically, recruitment efforts were focused 
at the University at Buffalo Department of Gynecology-Obstetrics practice plan and the 
University at Buffalo student health service.  A total of 957 prospective participants called 
the clinical center to inquire about the study. Of these, 449 scheduled and completed a 
screening visit. Of these, 318 met the eligibility criteria and 276 enrolled.  A diagram of the 
BioCycle recruitment is shown in Figure 4.2.  In order to be eligible to participate, women 
could not have used oral contraceptives during the past 3 months, be currently pregnant, or 
be actively trying to conceive during the next 3 months.  Only women reporting regular 
cycles and no history of gynecological or other chronic diseases were included.  A complete 
list of exclusion criteria is shown in Table 4.4.  A total of 259 women completed at least one 
cycle. Those eligible were fairly similar compared to those ineligible, although those eligible 
were slightly younger and more likely to report a white race. 
Of the 276 who enrolled, 250 completed two cycles, 9 completed one cycle, and 
seventeen women dropped out of the study prior to completing at least 1 cycle. Among the 
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259 women who completed at least 1 cycle, the number of study cycle visits ranged from 5 to 
8 per cycle (Table 4.2), with shorter menstrual cycle length as the primary reason for fewer 
than 8 visits completed per cycle.  This would occur if a woman began menstruating before 
the last scheduled visit on day 27.  Overall, 94% of all women completed 7 or 8 visits per 
cycle.  
Women that participated in the BioCycle study were mostly white (60%), single 
(68%), college-educated (90%), below the age of 30 (68%), with a normal BMI (60%).  
Baseline demographics are summarized in Table 4.3.  Overall, the mean age of participants 
was 27.3, and the mean BMI was 24.1.  Only 12% of participants were current smokers, and 
66% reported drinking at least 1 alcoholic drink per month in the past 6 months, with 37% 
reporting drinking at least 1 alcoholic drink per week.  Self-reported menstrual cycle length 
ranged from 21 to 35 days with a mean (standard deviation (SD)) length of 28.4 (2.2) days.  
This population has the advantage of having no reported gynecological problems, 
such as an abnormal Pap in the last 6 months with no subsequent normal result, laparoscopy 
confirmed endometriosis, treatment for infertility, uterine fibroids, or polycystic ovary 
disease.  It is important to exclude women with these conditions, because these gynecological 
problems have an impact on circulating hormone levels.  In addition, the age range of 18-44 
allows us to study women who have regular periods, without the issues of low gynecological 
age, or women entering the perimenopausal phase.   
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C. Fertility Monitor 
Each woman in the BioCycle study was given a fertility monitor (Clear Blue TM) 
which was used to determine the timing of ovulation and to schedule clinic visits at specific 
phases of the menstrual cycle (Figure 4.3).   
The monitors assessed fertility based on levels of estrone-3-glucuronide (E3G) (an 
estrone metabolite) and LH in urine.  Testing began on approximately the 6th day following 
the start of the woman’s menstrual cycle and continued for 10 or 20 days depending on the 
timing of the LH surge and cycle length.  Monitor indications of low, high and peak fertility 
were used to time mid-cycle visits, with peak day and the following 2 days being those that 
would approximately represent late follicular, LH surge, and ovulation dates.  Based on an 
approximate 28 day cycle length, the cycle visits represent approximately days 2, 7, 12, 13, 
14, 18, 22, and 27.  Overall, the women that participated in the BioCycle study were very 
compliant with the study protocol.  Table 4.5 shows that 48% of women did not miss a single 
test, and 80% missed only 0-2 days out of the entire cycle.  In addition, about 76% of cycles 
showed peak LH levels (Table 4.6), indicating that blood samples were collected at 
appropriate times with respect to ovulation. 
 There may be some misclassification among the 20% without an observed LH 
peak.  It is unclear to which direction this bias may impact the results.  However, this rate 
of misclassification is much lower than other methods which are commonly used to time 
sample collection to menstrual cycle phase.  In general, ovulation is said to occur on day 
14 of a 28 day cycle.30  If we were simply to collect samples on day 14 of a woman’s 
menstrual cycle, then we would have missed a significant portion of the LH peaks, 
because the mean peak day observed in this sample was on day 16 for cycle 1 and day 15 
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for cycle 2 (Table 4.6).  The fertility monitor is able to capture a far greater proportion of 
the LH peaks than other methods including sampling on days 12 to 14 of the cycle, or 
taking the midpoint of the self-reported cycle and taking samples the day before and the 
day after the midpoint, or counting back 13 to 15 days from the end of the cycle (Figure 
4.4). 
 Timing of biospecimen collection at 8 key times per cycle is one of the strengths 
of the study.  However, the complexity involved in aligning the cycles so that 
measurements can be compared is quite complex.  While use of the fertility monitor 
greatly improves timing of the cycle, there will of course be some variation in sample 
date collection.   
 
D. Statistical Analysis 
1. Overview 
Basic descriptive analyses were completed, along with appropriate bivariate analyses.  
Mean and median levels of hormone, lipoprotein, and dietary fiber intake levels were 
calculated for each cycle day and then compared across the cycle.  Distributional 
assumptions were evaluated graphically and using appropriate statistical tests, and 
transformations performed where necessary.  Data were stratified by age and BMI to 
determine the impact of these factors on exposures and outcomes of interest during the cycle.  
ANOVA, repeated measures ANOVA, t-tests, and chi-square tests were used as appropriate 
to determine whether differences in hormones, lipoproteins, and dietary fiber intake varied 
significantly across the cycle.   
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Marginal structural models (MSMs) were used to assess the impact of time-dependent 
confounding through the use of inverse-probability of treatment weights (IPTW).115  Levels 
of diet, physical activity, smoking, and alcohol consumption were allowed to vary at multiple 
time points during the menstrual cycle.  MSMs were used to evaluate the association between 
hormone and lipoprotein levels while accounting for the fact that these covariates vary over 
the cycle.  Due to the intricate nature of the hormonal fluctuations during the cycle, these 
models adequately control for the effects of the hormonal feedback mechanisms during the 
menstrual cycle.   
Weighted linear mixed effects models with random intercepts were used to estimate 
the coefficients of the marginal structural models.  These models were used to account for 
both intra- and inter-individual variability.  Linear mixed models have the advantage of being 
able to accommodate observations that are not independent, and are flexible in handling 
imbalanced longitudinal data.  The inclusion of random intercepts allowed for each subject to 
have a different baseline level of response.   
The main goals of the study analyses were: (Aim 1) to evaluate the association 
between serum estrogen and short-term changes in lipoprotein levels, (Aim 2) to evaluate the 
relationship between lipoprotein cholesterol levels and incident anovulation, and (Aim 3) to 
determine the direct and indirect effects of dietary fiber intake on lipoprotein cholesterol 
levels.  Details regarding the specific analysis for each aim are included in the Methods 
section of each Dissertation Manuscript chapter. 
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E. Tables and Figures 
Table 4.1.  Cycle visit schedule by cycle day (based on a 28-day cycle). 
Approximate 
Day of the 
Cycle 
Phase of the Cycle Expected Hormonal Variation* 
2 Menstrual Low E2, Low P Low LH/FSH 
  
 
7 Mid follicular Low E2, Low P Low LH/FSH 
  
 
12 Late Follicular Peak E2, Low P Low/Rising LH/FSH 
  
 
13 LH/FSH surge Peak LH/FSH Low E2, Low P 
  
 
14 Ovulation Decline LH/FSH, Low E2, Rising P 
  
 
18 Early Luteal Moderate E2, High P Low FSH/LH 
  
 
22 Mid Luteal Moderate E2, Peak P Low FSH/LH 
  
 
27 Late Luteal Decline E2, Decline P Low FSH/LH 
*E2=Estradiol, P=Progesterone, LH=Luteinizing Hormone, 
FSH=Follicle Stimulating Hormone 
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Table 4.2.  Number of visits per cycle for BioCycle participants. 
  Cycle 1 Cycle 2 
(N=259) (N=250) 
Number of visits N(%) N(%) 
5 3 (1.2) 2 (0.8) 
6 14 (5.4) 7 (2.8) 
7 57 (22.0) 52 (20.8) 
8 185 (71.4) 189 (75.6) 
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Table 4.3.  Baseline demographics of 259 women enrolled in the BioCycle study. 
  
N (%) 
Age (years)  
< 20 39 (15.1) 
20-29 136 (52.5) 
30-39 51 (19.7) 
> 40 33 (12.7) 
  Race  
White 154 (59.5) 
African American 51 (19.7) 
Other 54 (20.8) 
  Education (highest grade completed)  
< High school 33 (12.7) 
Post-secondary 226 (87.3) 
  Estimated median family income  
<$19,999 55 (21.2) 
$20, 000-39,999 61 (23.6) 
$40,000-74,999 72 (27.8) 
$75,000-99,000 45 (17.4) 
>$100,000 24 (9.3) 
Missing 2 (0.8) 
  Marital Status  
Married/Living as married 66 (25.5) 
Separated/Divorced 16 (6.2) 
Single 177 (68.3) 
  Body Mass Index (kg/m2)  
Underweight <18.5 10 (3.9) 
Normal 18.5 – 24.9 156 (60.2) 
Overweight 25.0 – 29.9 65 (25.1) 
Obese > 30.0 28 (10.8) 
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Table 4.4.  Inclusion/exclusion criteria for the BioCycle study. 
Inclusion Criteria 
• Age 18 to 44 at initial Screening Visit 
• Premenopausal 
• Self-reported cycle length between 21 and 35 days for each menstrual cycle for the past 6 
months 
• Willingness to provide regular fasting blood and urine specimens at our clinical center according 
to the proposed schedule of 8 visits per cycle times 2 cycles 
• Willingness and ability to complete regular study questionnaires and diaries 
 
Exclusion Criteria 
• Depo-provera, norplant or Intrauterine Device (IUD) use in the past 12 months 
• Oral Contraceptive use or other hormone supplement use in the past 3 months 
• Planning to attempt to conceive in the next 3 months 
• Reporting actively trying to conceive in the last 6 months 
• Pregnant currently or in the last 6 months  
• Breast feeding at any time in the last 6 months 
• Abnormal Pap in last 6 months with no subsequent normal result 
• Laparoscopy confirmed endometriosis 
• Current uterine fibroids or removal of a fibroid in the last 12 months 
• History of polycystic ovary disease 
• History of Chlamydia infection or positive IgG screen at screening 
• Untreated gynecologic infection or any genitourinary infection in the past 6 months  
• Gynecologic surgery in the past year 
• Sought treatment for infertility, ever (did not include male factor issues) 
• History or clinical signs of gynecologic problems (i.e.  
• Infectious disease treated by a physician in the past 6 months 
• Treatment for allergies with chronic medication (1 or more times per week in the last 3 months) 
• Liver or kidney disease requiring treatment in the past year 
• Psychiatric condition requiring medical therapy in the past year (including Premenstrual 
dysphoric disorder (PMDD)) 
• BMI (kg/m2) less than 18.0 or greater than 35.0 as measured in the clinic 
• Plan to consume a restricted diet for intended weight loss or medical reason in the next 3 months 
• Gastrointestinal conditions associated with malabsorption (i.e. Crohn’s disease) 
• Unwilling to stop regular intake of vitamin and/or mineral supplements or herbal antioxidant 
supplements during cycle visit months 
• Chronic use of certain medications, including lipid lowering drugs, anti-hypertensive 
medications and/or aspirin, among others 
• Antibiotic use in the past 3 months 
• History of chronic diseases such as heart disease, diabetes mellitus, cancer, inflammatory 
diseases, autoimmune, liver or kidney disease, thyroid disease or any other endocrine 
dysfunction  
• History of alcohol abuse/dependency disorder or other drug/substance abuse 
• Self-reported current regular illicit drug use in the past 30 days before baseline 
• Diets high in phyto-estrogen content (i.e. soy based diet) 
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Table 4.5.  Fertility monitor compliance among BioCycle study participants. 
    Cycle 1 Cycle 2 
    N   (%) N   (%) 
Incomplete monitor data 14 (5.6) 37 (16.0) 
Number of missed tests out of first 10 
0 120 (48.2) 98 (42.2) 
 1-2 83 (33.3) 77 (33.2) 
 3-4 23 (9.2) 27 (11.6) 
 5-10 22 (8.8) 18 (7.8) 
Unknown 1 (0.4) 12 (5.2) 
Luteinizing hormone level 
Peak 189 (75.9) 180 (77.6) 
No peak 49 (19.7) 29 (12.5) 
  Unknown 11   (4.4) 23   (9.9) 
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Table 4.6.  LH peak day based on fertility monitor data. 
  Cycle 1 Cycle 2 
  (n=186) (n=179) 
Mean SD Mean SD 
Peak day 16 3.4 15 3.4 
N (%) N (%) 
Visit on peak day 137 (73.7) 145 (81.0) 
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Figure 4.1.  Timing of blood sample collection in relation to pattern and timing of hormonal 
changes during the normal menstrual cycle.30 
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Figure 4.2.  BioCycle recruitment flow diagram. 
 
957 Calls Received 
449 Screening Visits Done 
131 Ineligible 
9 completed  
1 cycle  
318 Eligible 
250 completed 
2 cycles  
17 withdrew 
484 Not Interested or 
Self-screened out 
276 Enrolled 
24 Recruitment Ended 
Before Able to Join 
42 Not Enrolled 
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Figure 4.3.  ClearBlue®
 
 Fertility Monitor. 
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Figure 4.4.  Observation of LH peak based on different menstrual cycle timing methods. 
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V. Dissertation Manuscript #1: A Longitudinal Study of Serum Lipoproteins in Relation to 
Endogenous Reproductive Hormones during the Menstrual Cycle: Findings from the 
BioCycle Study  
A. Abstract 
It has been hypothesized that circulating endogenous estrogens protect 
premenopausal women from coronary heart disease.  The purpose of this study was to 
evaluate the association between lipoprotein and hormone levels across the normal menstrual 
cycle. Lipoprotein cholesterol and hormone levels were measured in serum from 259 healthy, 
regularly menstruating women in the BioCycle study. Fasting blood samples were collected 
at up to 16 points across 2 menstrual cycles, with collection scheduled using fertility 
monitors. We evaluated the relationship between estradiol and lipoproteins using marginal 
structural models with inverse probability of exposure weights. Total and low-density 
lipoprotein (LDL) cholesterol were lower during the luteal phase as compared to the 
follicular phase (P<0.001), and high-density lipoprotein (HDL) levels were highest around 
ovulation (P<0.001).  More women were classified above the desirable range (LDL≥130 
mg/dL or total cholesterol≥200 mg/dL) when measured during the follicular phase.  Estradiol 
was positively associated with HDL cholesterol in acute effects models (beta=0.016, 95% 
confidence interval (CI): 0.012, 0.019), and inversely associated with total cholesterol 
(beta=-0.015, 95% CI: -0.018, -0.012), LDL cholesterol (beta=-0.024, 95% CI: -0.028, -
0.019), and triglycerides (beta=-0.015, 95% CI: -0.027, -0.004) in persistent effects models.  
In conclusion, we observed that lipoprotein cholesterol levels varied across the cycle and 
were significantly associated with endogenous estrogen levels. This study supports the 
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beneficial effects of estrogen on lipoprotein cholesterol levels, and sheds light into the timing 
and mechanisms of estrogen’s effects, suggesting that they are not acute.  Cyclic variations 
have clinical implications regarding the appropriate timing of measurement during the cycle 
and may need to be considered in the design and interpretation of studies in women of 
reproductive age.  
 
B. Introduction 
Heart disease is the leading cause of death among women, primarily affecting 
postmenopausal women.1  The prevalence of coronary heart disease (CHD) among women 
20 to 39 years old is half the rate among men in the same age group (women, 7.8%; men, 
15.9%). The difference in prevalence of CHD between men and women holds despite 
adjustment for various risk factors.  However, as the prevalence of CHD among women 
increases with age, the difference between men and women drastically narrows.1 This has led 
to the hypothesis that circulating endogenous estrogens protect premenopausal women from 
CHD.  With this in mind, hormone therapy was recommended to postmenopausal women as 
a means of cardio-protection.2-5  However, results from the Women’s Health Initiative (WHI) 
trial6 and the Heart and Estrogen/progestin Replacement Study (HERS)7 found that hormone 
therapy improved lipoprotein profiles but was associated with increased rates of CHD, which 
suggested that the role of exogenous/endogenous hormones on CHD was more complicated 
than originally thought. 6-8     
The associations between exogenous sex hormones and lipoproteins seem to be well 
established.  Estrogen is thought to exert a favorable effect on lipoprotein metabolism by 
increasing very low density lipoprotein (VLDL) synthesis, inhibiting hepatic lipase and 
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lipoprotein lipase activity, and upregulating the LDL receptors.9-11  The effect of endogenous 
sex hormones on lipoprotein levels in healthy premenopausal women however, remains 
uncertain, as well as whether these effects are chronic versus acute.  Therefore, the objective 
of this study was to evaluate the association between serum estrogen and lipoprotein 
cholesterol levels during the normal menstrual cycle in a large prospective study of menstrual 
cycle function, with multiple measures of lipoprotein cholesterol and hormones throughout 
the cycle.   
 
C. Methods 
Study Sample 
The BioCycle study was a prospective cohort of 259 women who were followed for 
one (n=9) or two (n=259) cycles.116  Participants were recruited from healthy, premenopausal 
volunteers, aged 18 to 44, from western New York.  Exclusion criteria included current use 
of oral contraceptives or other medications including lipid lowering drugs, anti-hypertensive 
medications, and/or aspirin, pregnancy in the last 6 months, or a self-reported body mass 
index (BMI) at screening less than 18 or greater than 35.  Further details on inclusion and 
exclusion criteria have been reported elsewhere.116  The University at Buffalo Health 
Sciences Institutional Review Board approved the study. All participants provided written 
informed consent. 
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Data Collection 
The study involved up to 8 clinic visits per cycle for 2 cycles with visits timed using 
fertility monitors (Clearblue® Easy Fertility Monitor, Inverness Medical, Waltham, MA, 
USA) so that biospecimen collection occurred during specific phases of the cycle. Monitor 
indications of low, high, and peak fertility were used to time mid-cycle visits.  Visits 
corresponded to biologically relevant windows including menstruation, mid- and late-
follicular phase, LH/FSH surge, ovulation, and early-, mid-, and late-luteal phase. 
Participants were highly compliant with the study protocol—the number of visits ranged 
from 5 to 8 per cycle, with 94% of all women completing at least 7 visits per cycle.   
 
Hormone Assessment 
Estradiol, progesterone, LH, and FSH, were measured in fasting serum samples 
collected at each visit.  Estradiol, the principal estrogen secreted by the ovary, was measured 
using a radioimmunoassay.  Progesterone, LH, and FSH were measured using Solid phase 
competitive Chemiluminescent Enzymatic Immunoassay by Specialty Laboratories, Inc. 
(Valencia, CA) on the DPC Immulite®2000 analyzer (Siemens Medical Solutions 
Diagnostics, Deerfield, IL).  The analytical imprecision of these assays was monitored using 
3-level quality control materials as part of the laboratory’s quality assurance program.  
Across the study period the imprecision of all three quality control material levels was <5% 
coefficient of variation (%CV) for estradiol, LH, and FSH, and <10% CV for progesterone. 
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Lipoprotein Assessment 
A complete lipid profile was performed for each cycle visit.  The lipid profile 
included analysis of total cholesterol, HDL cholesterol, and triglycerides, using a Beckman 
LX20 automated chemistry analyzer at the Kaleida Center for Laboratory Medicine, Buffalo, 
NY.  LDL cholesterol was determined indirectly using the Friedewald formula.84  The 
analytical imprecision across the study period was <5% for all lipid and lipoprotein assays. 
 
Covariate Assessment 
Participants were asked to complete questionnaires on lifestyle (smoking status), 
physical activity (International Physical Activity Questionnaire long form 2002),117 and 
reproductive history.  Dietary intake was assessed using the 24-hour dietary recall 
methodology.  Recalls were conducted 4 times per cycle using the Nutrition Data System for 
Research (NDSR) software version 2005 developed by the Nutrition Coordinating Center 
(NCC), University of Minnesota, Minneapolis, MN.  Physical and anthropometric measures 
were done according to standardized protocols and included height, weight, and waist 
circumference.118   
 
Statistical Analysis 
Descriptive statistics were computed for all study variables according to tertile of 
baseline HDL and LDL cholesterol levels, as well as according to whether baseline LDL 
cholesterol levels were above the desirable range (≥ 130 mg/dL) according to the National 
Cholesterol Education Program (NCEP) guidelines.119  Baseline HDL and LDL levels were 
measured on the second day of menses during the first cycle under study.  Exact chi-square 
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tests and analysis of variance were used to test for associations between demographic 
variables and lipoprotein levels.  Median and interquartile range (IQR) levels of hormones 
and lipoprotein cholesterol were calculated for each clinic visit.  Both lipoprotein cholesterol 
and hormone levels were log transformed for normality.  Linear mixed models were used to 
compute the p-values for comparisons between the mean log values of hormones and 
lipoproteins across the cycle.   
Marginal structural models were used to model the association between lipoprotein 
cholesterol and estradiol levels measured on the same day (acute effects) or with estrogen 
levels at one visit predicting lipoprotein cholesterol levels at the next visit (persistent effects).  
Persistent effects models are intended to represent prolonged exposure to estrogen 
(approximately two days), and were considered to demonstrate temporality of effects.  
Lipoprotein cholesterol and hormone levels were allowed to vary over time and all models 
included hormone and lipoprotein cholesterol concentrations throughout the cycle, including 
up to 8 measurements per cycle.  Models were fit for each lipoprotein parameter (total, HDL, 
and LDL cholesterol, triglycerides, total cholesterol/HDL ratio).  In addition, since 
cholesterol is the initial precursor for steroid biosynthesis, we also evaluated the effect of 
baseline lipoprotein levels on hormone levels throughout the cycle.     
Weighted linear mixed effects models with random intercepts were used to estimate 
the variables of the marginal structural model using inverse probability of exposure weights 
to appropriately adjust for time-dependent confounding.115  In order to estimate the stabilized 
weights for each cycle visit under study, the conditional density of estradiol levels at each 
cycle visit while adjusting for other factors was obtained by ordinary least-squares regression 
and estimated by the normal distribution.115, 120  The choice of covariates in the weight 
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models was determined by a review of the literature and included age, BMI, and 
progesterone, LH, and FSH.  Additional measures of dietary intake, physical activity, 
smoking, alcohol use, and race were considered as potential covariates, but did not 
appreciably alter the estimates.  
Lastly, the percentage of women with cholesterol levels above the desirable ranges, as 
identified by the NCEP were calculated overall, and for each cycle day.119  Minimum and 
maximum lipoprotein cholesterol measurements across the cycle were calculated for each 
woman.  The percentage of women with minimum and maximum lipoprotein cholesterol 
measurements was calculated for each cycle day.  All statistical analyses were carried out 
using SAS version 9.1 (SAS Institute, Cary, NC, USA). 
 
D. Results 
Baseline characteristics varied somewhat by tertile of baseline HDL and LDL 
cholesterol levels and by whether a woman was considered to have “high” levels of LDL 
based on the NCEP guidelines (Table 5.1).  Specifically, older ages and a higher BMI and 
waist circumference were associated with higher levels of LDL cholesterol.  Higher levels of 
energy intake (kcals) and physical activity were observed among women with the most 
optimal lipid profiles.   
 Both hormone and lipoprotein cholesterol levels were observed to vary across the 
cycle (Table 5.2).  Hormone levels showed expected patterns of variation.  Total, LDL 
cholesterol, and triglycerides were highest during the follicular phase and declined during the 
luteal phase.  Specifically, median total cholesterol declined by 3.0% (p<.0001) and LDL 
cholesterol by 4.9% (p<.0001) from the mid-follicular phase to the mid-luteal phase.  HDL 
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cholesterol levels were highest during ovulation, but did not meaningfully change across 
other phases (p=1.0).   
In acute effects models, estradiol was positively associated with levels of total 
(p=0.0003) and HDL cholesterol (p<.0001), and inversely associated with the total 
cholesterol/HDL ratio (p<.0001) (Table 5.3).  In persistent effects models, estradiol was 
significantly inversely associated with total (p<.0001) and LDL cholesterol (p<.0001), total 
cholesterol/HDL ratio (p<.0001), and triglycerides (p=0.01).  Estradiol was also positively 
associated with HDL cholesterol (p=0.57), though this association was not significant.  In 
general, baseline lipoprotein levels were not significantly associated with hormone levels 
(results not shown).   
 The absolute changes in median lipoprotein cholesterol levels between women across 
the cycle were small (total cholesterol, -3.0%; HDL, 2.0%; LDL, -4.9%), however, the mean 
change within a woman over the cycle was much greater (i.e. total cholesterol, 19%).  In fact, 
the range of total cholesterol values within a woman over the 8 cycle visits was between 8 
and 85 mg/dL, with a mean of 27.7 (SD 11.1).   
In this study, only 5% (n=13) of women had total cholesterol levels above 200 mg/dL 
at all eight visits.  A total of 51 women (19.7%) had levels above 200 mg/dL on at least one 
cycle visit.  When measured during the late luteal phase the smallest percentage of women 
would be classified as having high cholesterol (total cholesterol, 7.9%; LDL cholesterol, 
10.5%), whereas the largest percentage are above the desirable levels during the follicular 
phase (total cholesterol, 14.3%; LDL cholesterol, 17.8%)  (Table 5.4).  45.0% of women had 
their maximum total cholesterol level throughout the cycle during the follicular phase; and 
45.4% of women had their minimum level during the luteal phase (Figure 5.1).  The 
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minimum between woman variability for these lipid measures was observed to occur during 
menses and during or immediately following ovulation (Figure 5.2).  Triglycerides and HDL 
cholesterol were observed to be highly variable throughout the cycle. 
 
E. Discussion 
In this longitudinal study of serum lipid profiles, we found that lipoprotein cholesterol 
levels varied across the cycle.  Specifically, total and LDL cholesterol were highest during 
the follicular phase and declined during the luteal phase, whereas HDL cholesterol was 
highest at ovulation.  In addition, we observed that increased levels of endogenous estrogen 
were associated with an improved lipid profile.  It appears that estrogen has a rapid effect on 
increasing HDL cholesterol levels.  However, the effects of estrogen on total and LDL 
cholesterol do not appear to be acute, as only prolonged exposure (approximately two days) 
was associated with decreased levels of total and LDL cholesterol.   
We observed significant changes in lipoprotein cholesterol measurements and 
variability throughout the cycle.  In fact, more women would be classified above the 
desirable range when tested during the follicular phase of the cycle.  Between-woman 
variability was reduced during menses and immediately following ovulation.  These 
differences in both mean and variance across the cycle suggest that cycle phase should be 
taken into account when evaluating lipoprotein cholesterol levels among reproductive aged 
women.  While treatment decisions may still require repeated samples above the 
recommended level, standardizing the timing of measurements may improve the 
interpretability of results and consequently reduce the overall number of tests.  It is 
interesting to note that these changes in classification and variability across the cycle were 
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observed among healthy women with no other risk factors for CHD.  It is possible that the 
variability in lipoprotein cholesterol could be much greater among women with multiple risk 
factors for CHD.  In fact, among obese women over 40 years of age in our study we observed 
increased variability across the cycle. 
These results are in line with several studies that have shown total and LDL 
cholesterol levels to be lower during the luteal phase of the cycle (when estrogen and 
progesterone levels are high), as compared to the follicular phase.63, 67, 68, 73-75, 86  In studies of 
exogenous hormones, however, progestins are usually considered to oppose the stimulatory 
effects of estrogen on lipoprotein metabolism.54  The luteal phase could be considered as a 
natural state of “opposed estrogen”, thus suggesting that endogenous progesterone may not 
exhibit the same opposing effects as exogenous progesterone.  We also observed HDL 
cholesterol levels to be highest around the time of ovulation, a finding that only a few 
previous studies have observed.70, 74, 121 This could be due to the fact that measurements 
compared between the follicular and luteal phases would tend to miss the peak levels of HDL 
cholesterol we observed to occur around ovulation.67, 78, 79, 86  Most previous studies observed 
no association between hormones and triglycerides,67, 71, 80-83, 122 but not all.73, 78  We 
observed an effect of hormones on triglycerides only in persistent effects models, suggesting 
that there may be a delay in the impact of estrogen on triglyceride levels.  Our results 
comparing acute and persistent effects of estrogen have not been previously addressed in the 
literature due to limited measures of hormones and lipoprotein cholesterol across the cycle in 
past studies.  
 As far as potential mechanisms, it is becoming clearer that endogenous estrogen 
affects lipoprotein metabolism at many points and in many beneficial ways, most 
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consistently with a decrease in plasma LDL cholesterol and an increase in HDL 
cholesterol.67, 80, 122-125  We know that, to some degree, the rates of formation of all 
lipoprotein fractions are increased under the influence of estrogen, but their removal rates are 
variably increased or decreased.9 Lipoprotein cholesterol levels are, however, imperfect 
markers of lipoprotein metabolism.  There is growing evidence that improvements to the 
atherogenic nature of the plasma lipid profile are in response to endogenous or exogenous 
estrogen. These changes are a function of effects including upregulation of the LDL receptors 
which act to increase the clearance of LDL cholesterol.126 the upregulation of ABCA1 (the 
ATP binding cassette transporter) and Apo-A1 which increases HDL synthesis,127 and the 
suppression of hepatic SR-BI (class B scavenger receptors) expression leading to decreased 
hepatic selective cholesterol uptake from HDL128 in addition to further effects on LDL.  The 
results of the present study support these findings in that we also observed estradiol to be 
associated with higher levels of HDL cholesterol in acute effects models and lower levels of 
LDL cholesterol in persistent effects models.   
These results suggest that estrogen has an acute effect on increasing HDL cholesterol.  
The accompanying rise observed in total cholesterol levels is most likely due to this increase 
in HDL cholesterol as we observed no accompanying associations with LDL.  As exposure to 
estrogen increased (persistent effects models), we observed a decline in total and LDL 
cholesterol, which could be indicative of a delayed impact of estrogen on upregulation of the 
LDL receptors.  Estrogen also stimulates removal of triglycerides from HDL which could 
explain the inverse association between estrogen and triglycerides, and the null association 
between estrogen and HDL cholesterol, we observed in persistent effects models.   
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Intensive monitoring on a large number of participants throughout 2 cycles, with 
multiple clinic visits timed using fertility monitors, are unique strengths of our study.  Our 
multiple measurements of both hormones and lipoproteins enabled us to more precisely 
model the association between estradiol and lipoprotein cholesterol levels, and to evaluate 
both acute and persistent effects.  Through the use of weighted linear mixed effects models 
we were also able to account for the correlation between and within women throughout the 
cycle, while taking levels of other reproductive hormones into account (adjusting for time-
varying confounding).  The prospective design and exclusion criteria at baseline strengthen 
the ability to draw inference, having reduced the potential for bias from factors known to be 
associated with lipoprotein levels.  Standardized assessment of a wide variety of participant 
and dietary characteristics increased the ability to adjust for potential confounding factors in 
the weight models.   
There are several limitations worth noting.  Residual confounding is a possibility, 
since it can be very difficult to capture effects of dietary intake and exercise.  The fact that 
adjustment for these factors did not appreciably alter the results for any of the models could 
partially be due to misclassification of these covariates.  While our study sample population 
was restricted to normally menstruating women to exclude potential confounders by design, 
such restrictions could also limit the generalizability of our findings.  There may be some 
selection bias due to loss to follow-up over the cycle as not all women completed 8 visits per 
cycle, however, marginal structural models account for this loss to follow-up through inverse 
probability of exposure weighting.  Also, there is the potential for some misclassification of 
cycle phase as not all LH peaks were captured on the monitor.  The increase in total 
cholesterol observed during the follicular phase could be due, at least in part, to the reduction 
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in plasma volume observed during this phase of the cycle which we were unable to 
evaluate.63, 73, 129 The observed changes in HDL cholesterol around ovulation, however, 
appear to be independent from the expected increase in plasma volume.  Although we cannot 
completely account for temporality of the effects of hormones and lipoproteins, we observed 
no significant effects of baseline lipoprotein levels on hormones throughout the cycle.  
Finally, while the use of marginal structural models was a significant improvement over 
traditional covariate assessment, they are based on certain strong assumptions such as no 
unmeasured confounding, positivity, correct model specification, and consistency.  These 
assumptions are generally hard to meet and should be taken into consideration when 
interpreting results.115, 120   
 In conclusion, cholesterol levels varied and were associated with endogenous 
estrogen levels across the cycle. This study confirms the hypothesized beneficial effects of 
endogenous estrogen on lipoprotein cholesterol levels, and suggests that the effects of 
estrogen on lowering total and LDL cholesterol are not acute. This study is the first to 
evaluate the association between endogenous estrogen and lipoproteins using multiple and 
longitudinal serum measures of estrogen and lipoproteins, while comprehensively 
considering potential impacts from other reproductive hormones.  More importantly, this 
research helps to fill an etiological gap in understanding the relationship between lipoprotein 
cholesterol changes induced by hormonal variations during the menstrual cycle.  Cyclic 
variations in lipoprotein cholesterol levels observed in the present study have clinical 
implications regarding the appropriate timing of lipoprotein cholesterol measurement during 
the menstrual cycle and should be accounted for in the design and interpretation of studies in 
women of reproductive age.  Our research on the effects of estrogen on lipid profiles, a 
64 
 
significant risk factor for cardiovascular disease, helps clarify the role of endogenous 
estrogen in cardio-protection and should be used to inform the direction of future research in 
pre- and post-menopausal women. 
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F. Tables and Figures 
Table 5.1.  Characteristics of women in the BioCycle study by tertile of baseline HDL and LDL cholesterol (n=259). 
    
HDL Cholesterol tertile 
 
LDL Cholesterol tertile 
 
NCEP Guidelines - 
LDL Cholesterol* 
Overall 
<44 
mg/dL 
44-54 
mg/dL 
>54 
mg/dL 
<92 
mg/dL 
92-107 
mg/dL 
>107 
mg/dL 
<130 
mg/dL 
≥130 
mg/dL 
  N=259 n=86 n=85 n=86 n=87 n=84 n=86 n=224 n=33 
Age – yr† 27.3 ± 8.2 26.4 ± 7.8 27.7 ± 8.2 27.7 ± 8.6 25.4 ± 7.5 27.3 ± 8.2 29.2 ± 8.6 26.6 ± 7.8 32.1 ± 9.5 
BMI – kg/m2 24.1 ± 3.9 25.3 ± 3.9 23.7 ± 3.4 23.1 ± 3.8 23.6 ± 3.5 23.6 ± 4.0 24.9 ± 3.8 23.8 ± 3.7 26.0 ± 3.8 
Waist circumference 
(cm) 74.7 ± 8.7 76.9 ± 9.0 74.9 ± 7.3 72.2 ± 8.9 72.9 ± 7.3 74.6 ± 9.4 76.6 ± 8.7 74.1 ± 8.4 78.9 ± 8.8 
Race – n (%) 
White 154 (59) 45 (52) 52 (61) 56 (65) 50 (57) 51 (61) 52 (60) 135 (60.3) 18 (54.6) 
African American 51 (20) 19 (22) 14 (16) 17 (20) 20 (23) 12 (14) 18 (21) 40 (17.9) 10 (30.3) 
Other 54 (21) 22 (26) 19 (22) 13 (15) 17 (20) 21 (25) 16 (19) 49 (21.9) 5 (15.2) 
Less than high school 
education – n (%) 33 (13) 16 (19) 7 (8) 9 (10) 8 (9) 12 (14) 12 (14) 25 (11.2) 7 (21.2) 
Married – n (%) 66 (26) 14 (16) 24 (28) 27 (31) 18 (21) 20 (24) 27 (31) 54 (24.1) 11 (33.3) 
Physical activity category – n (%) 
Low 25 (10) 9 (10) 8 (9) 8 (9) 11 (13) 4 (5) 10 (12) 23 (10.3) 2 (6.1) 
Moderate 92 (36) 34 (40) 28 (33) 30 (35) 20 (23) 39 (46) 33 (38) 78 (34.8) 14 (42.4) 
High 142 (55) 43 (50) 49 (58) 48 (56) 56 (64) 41 (49) 43 (50) 123 (54.9) 17 (51.5) 
Energy (kcal) 
1603.5 ± 
397.7 
1582.8 ± 
383.1 
1604.9 ± 
421.1 
1625.5 ± 
396.0 
1638.0 ± 
375.5 
1614.1 ± 
445.5 
1560.9 ± 
374.4 
1603.7 ± 
402.6 
1609.0 ± 
380.8 
Nulliparous – n (%) 187 (74) 64 (75) 61 (73) 61 (73) 69 (80) 61 (74) 56 (67) 168 (76.0) 18 (60.0) 
Current smoker – n (%) 10 (3.9) 3 (3) 3 (3) 4 (5) 3 (3) 4 (5) 3 (3) 9 (4.0) 1 (3.0) 
BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein; NCEP, National Cholesterol Education Program; SD, standard 
deviation. 
*LDL Cholesterol <130 mg/dL is considered “optimal” or “near optimal/above optimal” and ≥130 mg/dL is considered “borderline high,” “high”, or 
“very high” according to the NCEP; †Values are mean ± SD; ‡HDL p-value <0.05; §LDL p-value <0.05; ║NCEP p-value <0.05 
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Table 5.2.  Serum hormone and lipoprotein cholesterol concentrations among women in the BioCycle study (n=259) by menstrual 
cycle phase. 
  Menses 
Mid-
Follicular 
Late 
Follicular 
LH/FSH 
Surge Ovulation Early Luteal 
Mid- 
Luteal 
Late  
Luteal 
Estrogen 
(pg/mL)† 33.0 (20.0) 48.0 (37.0) 
121.0 
(155.0) 
116.0 
(153.0) 96.0 (111.0) 117.0 (93.0) 122.0 (91.5) 75.0 (79.0) 
Progesterone 
(ng/mL)† 0.5 (0.3) 0.4 (0.3) 0.6 (0.6) 0.9 (1.2) 1.7 (3.0) 7.4 (10.0) 8.9 (7.4) 4.0 (6.3) 
LH (ng/mL)† 3.9 (2.4) 4.7 (3.0) 7.6 (10.6) 10.3 (14.6) 8.5 (10.9) 6.4 (6.2) 4.3 (4.6) 4.0 (3.4) 
FSH 
(mIU/mL)† 6.3 (2.5) 6.4 (2.5) 6.2 (4.0) 6.8 (5.3) 6.3 (5.3) 4.4 (3.8) 3.1 (2.5) 3.4 (2.3) 
Total 
Cholesterol 
(mg/dL)† 160.0 (36.0) 166.0 (39.0) 164.0 (38.0) 164.0 (34.0) 162.0 (34.0) 161.0 (35.0) 161.0 (36.0) 157.0 (40.5) 
HDL 
Cholesterol 
(mg/dL)† 48.0 (17.0) 50.0 (17.0) 52.0 (17.0) 52.0 (16.0) 52.0 (16.0) 52.0 (16.0) 51.0 (16.0) 50.0 (17.0) 
LDL 
Cholesterol 
(mg/dL)† 98.0 (32.0) 102.0 (33.0) 100.0 (32.0) 98.5 (32.0) 98.0 (30.0) 96.0 (31.0) 97.0 (34.0) 96.0 (34.5) 
Triglycerides 
(mg/dL)§ 51.5 (32.0) 56.0 (33.0) 55.0 (30.0) 51.0 (28.0) 53.0 (27.0) 53.0 (31.0) 51.0 (28.0) 49.0 (28.0) 
Total 
Cholesterol/H
DL Ratio‡ 3.3 (1.0) 3.3 (1.2) 3.2 (1.1) 3.1 (1.0) 3.1 (1.0) 3.1 (0.9) 3.1 (1.0) 3.2 (1.1) 
FSH, follicle stimulating hormone; HDL, high density lipoprotein; IQR, interquartile range; LDL, low density lipoprotein; LH, luteinizing 
hormone. 
*Results presented are Median (IQR) 
† P < 0.0001; P-values from repeated measures ANOVA based on log transformed values.  
‡ P < 0.01; § P < 0.10 
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Table 5.3.  Association between log(estrogen) and log(lipoprotein cholesterol) levels among 
women participating in the BioCycle study (n=259).  Results are based on marginal structural 
models with inverse probability of exposure weights. 
  Effects*  Beta† 95% CI p-value 
Total Cholesterol (mg/dL) Acute 0.0049 (0.0022, 0.0076) 0.0003 
 Persistent -0.0150 (-0.0178, -0.0122) <.0001 
HDL Cholesterol (mg/dL) Acute 0.0156 (0.0121, 0.0192) <.0001 
 Persistent 0.0011 (-0.0026, 0.0047) 0.57 
LDL Cholesterol (mg/dL) Acute -0.0012 (-0.0053, 0.0029) 0.56 
 Persistent -0.0236 (-0.0278, -0.0194) <.0001 
Total Cholesterol/HDL 
Ratio Acute -0.0120 (-0.0151, -0.0088) <.0001 
 Persistent -0.0178 (-0.0210, -0.0145) <.0001 
Triglycerides (mg/dL) Acute -0.0021 (-0.0132, 0.0090) 0.71 
    Persistent -0.0169 (-0.0282, -0.0056) 0.004 
BMI, body mass index; CI, confidence interval; HDL, high density lipoprotein; LDL, low density 
lipoprotein. 
*Acute effects models model the association between estrogen and lipoproteins measured on the 
same day.  Persistent effects models model the association between estrogen measured at one visit 
and lipoprotein cholesterol levels at the next visit. 
†Inverse probability of exposure weights were used to adjust for confounding.  Weight models 
adjusted for hormone levels on previous days of the cycle.  All weight models adjusted for age and 
BMI, weights for triglyceride models also adjusted for physical activity, race, alcohol use, smoking, 
and trans fatty acid intake. 
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Table 5.4.  Women participating in the BioCycle study (n=259) above desirable ranges of total, HDL, and LDL cholesterol at 
each cycle visit during cycle one as defined by the National Cholesterol Education Program (NCEP), n (%).119 
Menses 
Mid-
Follicular 
Late 
Follicular 
LH/FSH 
Surge Ovulation 
Early 
Luteal 
Mid-
Luteal 
Late 
Luteal 
n (%) n=257 n=258 n=259 n=258 n=257 n=252 n=244 n=191 
Total Cholesterol ≥200 mg/dL 26 (10.1) 37 (14.3) 29 (11.2) 28 (10.9) 27 (10.5) 23 (9.1) 23 (9.4) 15 (7.9) 
Total Cholesterol ≥240 mg/dL  5 (1.9) 4 (1.6) 6 (2.3) 6 (2.3) 5 (1.9) 5 (2.0) 4 (1.6) 4 (2.1) 
LDL Cholesterol ≥ 130 mg/dL 34 (13.2) 46 (17.8) 36 (13.9) 27 (10.5) 29 (11.3) 28 (11.1) 27 (11.1) 20 (10.5) 
LDL Cholesterol ≥ 160 mg/dL 5 (1.9) 5 (1.9) 5 (1.9) 5 (1.9) 6 (2.3) 4 (1.6) 4 (1.6) 5 (2.6) 
HDL Cholesterol <40 mg/dL 43 (16.7) 42 (16.3) 32 (12.4) 34 (13.2) 32 (12.5) 36 (14.3) 38 (15.6) 39 (20.4) 
FSH, follicle stimulating hormone; HDL, high density lipoprotein; LDL low density lipoprotein; LH, luteinizing hormone; NCEP, 
National Cholesterol Education Program 
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Figure 5.1. Day of maximum or minimum total cholesterol concentration across the cycle among women participating in the 
BioCycle study (n=259). 
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Figure 5.2.  Between woman variance of total, HDL, and LDL cholesterol and triglycerides 
by cycle visit among women participating in the BioCycle study (n=259). 
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VI. Dissertation Manuscript #2:  Lipoprotein Cholesterol Levels and Anovulation among 
Normally Menstruating Premenopausal Women 
 
A. Abstract 
Sporadic anovulatory cycles may be fairly common among regularly menstruating 
women, and reproductive hormone levels are intricately tied to ovulation.  As cholesterol is 
the initial precursor for steroid biosynthesis, lipoprotein cholesterol levels are hypothesized 
to be associated with anovulation, however this remains to be tested. The objective of this 
study was to evaluate the association between lipoprotein cholesterol levels and incident 
anovulation among women reporting regular menstruation.  The BioCycle Study was a 
prospective cohort study conducted at the University at Buffalo from September 2004 to 
2006, which followed 250 self-reported regularly menstruating women aged 18 to 44, for two 
menstrual cycles.  Women with at least one anovulatory cycle displayed higher mean levels 
of total and LDL cholesterol and triglycerides (adjusted for age and BMI), as well as several 
markers of endocrine function.  Total cholesterol levels preceding the predicted time of 
ovulation were weakly associated with an increased risk of incident anovulation (OR per 5 
mg/dL: 1.09, 95% CI: 1.01-1.18), however after adjustment for age at menarche and the 
LH:FSH ratio there was further attenuation (OR per 5 mg/dL: 1.06, 95% CI: 0.98-1.15).  
Markers of endocrine function (increased LH:FSH ratio, acne, and insulin levels and 
decreased SHBG) were significant predictors of anovulation.  In conclusion, anovulatory 
women showed a more atherogenic lipid profile and endocrine characteristics indicative of 
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hyperandrogenism–findings that are consistent with retrospective data reported for women 
with polycystic ovary syndrome (PCOS).  Lipoprotein cholesterol levels were weakly 
associated with risk of anovulation, however we identified that LH:FSH ratio, SHBG, 
insulin, and acne were predictors of incident anovulation.  Collectively, these markers are 
consistent with mild hyperandrogenism coincident to anovulation, and may be indicative of a 
mild undiagnosed PCOS phenotype.  This is the first study to our knowledge to prospectively 
identify endocrine markers of sporadic anovulation in a group of regularly menstruating 
women.  Further studies are needed to elucidate the biological mechanisms that lead to 
sporadic anovulation. 
 
B. Introduction 
Sporadic anovulatory cycles may be fairly common among regularly menstruating 
women, although they are difficult to detect and the prevalence of anovulation has not been 
well described.12  The factors associated with anovulatory cycles are also not well understood 
among regularly menstruating women, but are of interest as anovulation might be associated 
with infertility.  Ovulatory disorders are one of the leading causes of female infertility, 
affecting between 18 and 30% of infertile couples.130, 131  Reproductive hormone levels are 
intricately tied to ovulation through regulation of the hypothalamic-pituitary-ovarian axis.  
As cholesterol is the initial precursor for steroid biosynthesis and plays a central role in the 
synthesis of sex hormones, lipoprotein cholesterol are hypothesized to be associated with 
anovulation.12   
There is some evidence of a more atherogenic lipid profile (increased levels of total 
cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides, and decreased 
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levels of high-density lipoprotein (HDL) cholesterol) among women with certain ovulatory 
disorders, specifically among women with polycystic ovary syndrome (PCOS).13  However, 
the association between lipoprotein cholesterol and anovulation, in the absence of diagnosed 
PCOS, has not been well characterized.  A broad spectrum of severity and variability in 
PCOS has been reported, and according to recently updated diagnostic criteria it appears that 
there exist subgroups of women with milder forms of the syndrome that may differ from 
classic PCOS in gonadotropin and hormone secretion patterns, as well as degree of 
dyslipidemia.132-134 Past studies have generally relied on the case-control design to evaluate 
these relationships, however they have described lipid profiles only between PCOS and non-
PCOS women.  To our knowledge the association between lipoprotein cholesterol levels and 
anovulation has not been directly evaluated.  Moreover, these relationships have not been 
prospectively evaluated in regularly menstruating women, free of diagnosed PCOS.13   
Therefore, the objective of this study was to prospectively evaluate the association 
between serum lipid and lipoprotein cholesterol levels at baseline, and at multiple time points 
preceding the predicted time of ovulation, and incident anovulation among a group of 
regularly menstruating women. 
 
C. Methods 
Study Sample 
The BioCycle study was a prospective cohort of 259 women who were followed for 
one (n=9) or two (n=250) cycles.116  Participants were recruited from healthy premenopausal 
volunteers aged 18 to 44 from the western New York region.  Exclusion criteria included 
current use of oral contraceptives, or other medications including lipid lowering drugs, anti-
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hypertensive medications, and aspirin, pregnancy in the last 6 months, chronic disease, or a 
self-reported body mass index (BMI) at screening less than 18 or greater than 35.  Full details 
on inclusion and exclusion criteria have been reported elsewhere.116  The University at 
Buffalo Health Sciences Institutional Review Board approved the study and all participants 
provided written informed consent. 
 
Data Collection 
The study involved 5 to 8 clinic visits per cycle (94% of all women completed at least 
7 visits per cycle) for up to 2 cycles, with visits timed using fertility monitors (Clearblue ® 
Easy Fertility Monitor, Inverness Medical, Waltham, MA, USA) so that biospecimen 
collection occurred during specific phases of the menstrual cycle.  Monitors measured 
estrone-3-glucuronide and luteinizing hormone (LH) in urine daily starting on the 6th day 
following the start of the woman’s menstrual cycle.  Monitor indications of low, high, and 
peak fertility were used to time mid-cycle visits.  If by day 14 there was no positive 
indication on the monitor, a visit was scheduled the following day while the participant 
continued daily monitor testing for 10 additional days.  This new technology was used to 
more accurately define menstrual cycle phase, representing a significant improvement over 
previous studies.135  Visits corresponded to biologically relevant windows including 
menstruation, mid- and late-follicular phase, LH and follicle stimulating hormone (FSH) 
surge, ovulation, and early-, mid-, and late-luteal phase.    
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Laboratory Assays 
Estradiol, progesterone, LH, FSH, sex hormone-binding globulin (SHBG), glucose, 
and insulin were measured in fasting serum samples collected at each visit.  Fasting morning 
blood draws were collected between 7:00 a.m. and 8:30 a.m. at each visit and processed 
according to standardized protocols.136  Samples were then frozen at -80oC and sent as 
complete participant cycle batches to Kaleida Health Center for Laboratory Medicine 
(Buffalo, NY) for analysis of hormone concentrations.  Estradiol was measured using a 
radioimmunoassay.  Progesterone, LH, FSH, SHBG, and insulin were measured using a solid 
phase competitive chemiluminescent enzymatic immunoassay by Specialty Laboratories, Inc. 
(Valencia, CA) on the DPC Immulite®2000 analyzer (Siemens Medical Solutions 
Diagnostics, Deerfield, IL).  The analytical imprecision of these assays was monitored using 
3-level quality control materials as part of the laboratory’s quality assurance program.  
Across the study period the imprecision was <5% for the inter-assay variability in estradiol, 
LH, and FSH levels, and <10% for levels of progesterone, SHBG, and insulin.  Fasting 
plasma glucose was assayed using a hexokinase based methodology on a Beckman LX20 
autoanalyzer and inter-assay variability was <3%.  Insulin resistance (HOMA-IR) was 
calculated based on the homeostasis model using the equation: fasting insulin (µU/ml) x 
fasting glucose (mmol/l) / 22.5.137 
A complete lipid profile was also performed for each participant at each cycle visit.  
The lipid profile included analysis of total cholesterol, HDL cholesterol, and triglycerides, 
and was measured using a Beckman LX20 automated chemistry analyzer at the Kaleida 
Center for Laboratory Medicine (Buffalo, NY).  LDL cholesterol was determined indirectly 
using the Friedewald formula.84  The analytical imprecision across the study period was < 
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5% for all lipid and lipoprotein assays.  Baseline total cholesterol, HDL, LDL, and 
triglyceride levels were assessed on the second day of menses during the first cycle under 
study. 
 
Classification of Anovulation   
Menstrual cycles were initially classified as anovulatory if the peak progesterone 
concentration across the cycle was ≤5 ng/mL (n=65).138, 139 To minimize misclassification, 
we employed a conservative definition for ovulation in which cycles with progesterone 
concentrations ≤5 ng/mL and an observed serum LH peak on the mid- or late luteal phase 
visit were considered ovulatory cycles. Based on this algorithm, 42 of the 509 cycles (8.3%) 
in this study were classified as anovulatory. Overall, 35 (13.5%) women had at least one 
anovulatory cycle; 28 (10.8%) women had one anovulatory cycle and 7 (2.7%) women had 
two anovulatory cycles. 
 
Covariate Assessment 
Participants were asked to complete questionnaires on demographic characteristics, 
lifestyle (smoking status), physical activity (International Physical Activity Questionnaire 
long form 2002),117  body hair patterns (modified Ferriman-Gallwey hirsutism score),140 
acne, and reproductive history.  Physical and anthropometric measures were according to 
standardized protocols and included height, weight, and waist and hip circumference.118  
Dietary intake was assessed on several of the same days as biologic sample collection using 
the 24-hour recall methodology.  Recalls were conducted 4 times per cycle, for a total of up 
to 8 recalls, using the Nutrition Data System for Research (NDSR) software version 2005 
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developed by the Nutrition Coordinating Center (NCC), University of Minnesota, 
Minneapolis, MN.  Average dietary consumption across the cycle was calculated for each 
nutrient of interest.  Cycle length was defined as the number of days from the first day of 
bleeding (menstruating by 4:00 p.m.) until the day before the next onset of bleeding.   
 
Statistical Analysis 
Descriptive statistics were computed for all study variables and compared between 
women with 0, 1, or 2 anovulatory cycles.  Analysis of variance (ANOVA) was used to test 
for differences in means, and chi-square tests were used to test for differences in categorical 
variables.  Mean levels of baseline lipoprotein cholesterol, and levels of lipoprotein 
cholesterol at multiple points across the cycle, were compared between ovulatory and 
anovulatory women, both unadjusted and adjusted for age and BMI.  Linear mixed models 
were used to calculate predicted mean values and 95% confidence intervals (CIs) of age- and 
BMI-adjusted lipoprotein cholesterol levels at baseline according to ovulatory status, as well 
as age- and BMI-adjusted markers of endocrine function according to ovulatory status.  
Geometric means are presented for non-normally distributed variables. 
Generalized linear mixed models with random intercepts were used to model the 
association between lipoprotein cholesterol levels (total cholesterol, HDL, and LDL 
cholesterol, and triglycerides) and the probability of incident anovulation across two 
menstrual cycles. Adjusted odds ratios (aORs) and CIs were calculated to represent a 5 
mg/dL change in lipoprotein levels.  We considered the effects of baseline lipoprotein 
cholesterol levels on anovulation, as well as the effects of lipoprotein cholesterol levels up to 
the time of expected ovulation and anovulation in a given cycle.  At baseline we assumed 
 78 
 
that lipoprotein cholesterol levels would not be affected by reproductive hormones, as 
hormone levels are typically low during menses and any influence should be minimal at this 
point.  All models were adjusted for age, BMI, fiber intake, and total energy.  We also 
compared results after adjusting for age at menarche, and each LH:FSH ratio, HOMA-IR, 
insulin, SHBG, hirsutism score, and current acne, in order to determine whether the observed 
associations could be explained by confounding due to underlying endocrine disturbances.   
For models of the association between lipoprotein cholesterol levels up to the time of 
expected ovulation and anovulation, we included up to 4 lipoprotein cholesterol 
measurements per cycle for each woman, corresponding to menses, mid- and late-follicular 
phase, and the LH/FSH surge.  Stabilized inverse probability of exposure weights were used 
to adjust for time-dependent confounding due to changing hormone levels across the cycle.  
Stabilized weights were estimated by the conditional probability density of lipoprotein 
cholesterol levels at each visit given a woman’s age, BMI, fiber intake, total energy, and 
levels of estrogen, LH, and FSH over the cycle.  Estimates were obtained by ordinary least 
squares regression and estimated by the normal distribution.115, 120  Weight model 
misspecification was explored by checking the distribution of the weights for different 
choices of covariates in the weight model.  The choice of covariates was determined by 
literature review.   
We further evaluated the women in our study with both an ovulatory and anovulatory 
cycle (n=23).  We compared day 2 lipoprotein cholesterol levels between cycles using paired 
t-tests and generated ORs and 95% CIs for the association between lipoprotein cholesterol 
levels and anovulation adjusted for the LH:FSH ratio.  SAS version 9.1 (SAS Institute, Cary, 
NC, USA) was used for all statistical analyses.   
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D. Results 
The women in the BioCycle study were on average 27.3 years of age (range 18 to 44) 
and consisted mainly of single, nulliparous, normal weight, White women with some post-
secondary education.  Number of anovulatory cycles (0, 1, 2) differed significantly according 
to age, marital status, parity, and years since menarche (Table 6.1). Women with anovulatory 
cycles were on average younger, single, nulliparous, and with fewer years since menarche.  
Women with two anovulatory cycles also had shorter cycles on average.  Age at menarche 
was similar between the three groups, although we noted a slight increase among the women 
with two anovulatory cycles (0.5 years older). After adjustment for age and BMI, we 
detected an upward trend in baseline triglyceride levels with increasing number of 
anovulatory cycles.  Similarly, women with anovulatory cycles tended to have higher total 
and LDL cholesterol levels at baseline, however these differences were not statistically 
significant. When multiple measures of lipoprotein cholesterol levels were evaluated across 
the cycle, we observed significantly higher levels of total (p=0.01) and LDL (p=0.06) 
cholesterol and triglycerides (p=0.0002) in anovulatory as compared to ovulatory women 
(results not shown).  No differences were observed with HDL cholesterol (p=0.8).   
 Several markers of endocrine function were evaluated and compared between 
anovulatory and ovulatory women, after adjusting for age and BMI (Table 6.2).  Hirsutism 
scores and waist-to-hip ratios did not differ significantly between women with 0, 1, or 2 
anovulatory cycles.  However, prevalence of current acne was significantly higher among 
women with one or two anovulatory cycles, with the prevalence increasing with the number 
of anovulatory cycles observed.  LH:FSH ratios were significantly higher (for day 2, day 7, 
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and the average of days 2 and 7), and SHBG levels (day 2) were significantly lower among 
anovulatory women, with dose-response relationships observed corresponding to the number 
of anovulatory cycles.  Glucose, insulin, and HOMA-IR levels were not significantly 
different between the three groups, although women with at least one anovulatory cycle had 
higher insulin and HOMA-IR values on average.  
Baseline lipoprotein cholesterol levels were not found to be associated with risk of 
anovulation for any of the lipoprotein cholesterol parameters, regardless of model choice 
(Table 6.3).  When levels of lipoprotein cholesterol were allowed to vary up to the time of 
expected ovulation, we saw weak evidence of an association between total cholesterol and 
risk of anovulation (OR per 5 mg/dL: 1.09, 95% CI: 1.01, 1.17).  However, these results were 
attenuated after adjustment for age at menarche (OR per 5 mg/dL: 1.07, 95% CI: 0.99, 1.15).  
Further adjustment for the LH:FSH ratio did not appreciably alter the results (OR per 5 
mg/dL: 1.07, 95% CI: 0.99, 1.16).  We also adjusted for HOMA-IR, insulin, SHBG, 
hirsutism score and current acne, but the results remained unchanged (data not shown).  We 
did not observe any associations between HDL, LDL, triglycerides and anovulation 
regardless of covariate choice.  In all models we observed that in addition to age, an 
increased LH:FSH ratio on day 2 and decreased SHBG on day 2 were predictive of sporadic 
anovulation in a given cycle, when considering changing levels of lipoprotein cholesterol.  
Elevated insulin levels were predictive of anovulation in models of total and LDL 
cholesterol, but not triglycerides, and presence of current acne was predictive of anovulation 
in models of total cholesterol and triglycerides.  Hirsutism score was not found to be 
predictive of anovulation.  Odds ratios for these covariates are displayed in Figure 6.1.   
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To account for time-invariant measured and unmeasured confounders, we evaluated 
the 23 women with both an ovulatory and anovulatory cycle during the study period.  We 
observed that mean day 2 total cholesterol, LDL cholesterol, and triglyceride levels were 
higher preceding the anovulatory cycle.  The mean paired difference was 7.6 mg/dL for total 
cholesterol (p=0.03), 5.1 mg/dL for LDL cholesterol (p=0.07), and 10.3 mg/dL for 
triglycerides (p=0.05).  There was no difference in HDL cholesterol levels (p=0.9).  Overall, 
higher total and LDL cholesterol, and triglyceride level were associated with an increased 
risk of anovulation among these women, even after adjustment for the LH:FSH ratio (Figure 
6.2). 
 
E. Discussion 
 In this prospective cohort of normally menstruating women, the women who 
experienced an anovulatory cycle showed a more atherogenic lipid profile along with several 
endocrine characteristics consistent with hyperandrogenism.  We observed a weak 
association between total cholesterol levels preceding the predicted time of ovulation and 
anovulation, that was attenuated after adjustment for age at menarche and the LH:FSH ratio. 
Further, among women with both an ovulatory and anovulatory cycle during the study 
period, lipoprotein cholesterol levels on day 2 of menses were higher preceding anovulatory 
cycles and were associated with an increased risk of anovulation.  Increased day 2 LH:FSH 
ratio, levels of insulin, the presence of acne, and decreased levels of SHBG were found to be 
predictive of an anovulatory cycle.  Collectively, these markers are consistent with mild 
hyperandrogenism and may be indicative of an undiagnosed mild PCOS phenotype.  To our 
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knowledge, this is the first study to prospectively identify endocrine markers of sporadic 
anovulation in a group of regularly menstruating women.   
Associations between lipid profiles and anovulation are typically described among 
women with PCOS, a disorder associated with menstrual disruption (such as irregular 
ovulatory cycles) and hormonal abnormalities characterized by hyperandrogenism, in the 
absence of related disorders.132, 141, 142  According to recently updated diagnostic criteria, the 
diagnosis of PCOS has broadened and only requires presence of two of the following three 
criteria: hyperandrogenism, ovulatory dysfunction, and the presence of polycystic ovaries.141  
This expanded definition has led to the identification of four potential PCOS phenotypes 
(anovulatory PCOS-with or without polycystic ovaries (‘classic’ PCOS), ovulatory PCOS, 
and nonhyperandrogenic), representing a spectrum of severity and variability in metabolic 
parameters, body composition, and cardiovascular disease risk.143  The more atherogenic 
lipid profile we observed among the anovulatory women in our study is consistent with 
previous research among women diagnosed with PCOS,144-148 including those exhibiting a 
mild phenotype.133  The degree of dyslipidemia also appears to depend on phenotype, with 
ovulatory PCOS women displaying a milder form of atherogenic dyslipidemia than 
anovulatory PCOS women.133  In a recent retrospective study which evaluated the extent of 
atherogenic dyslipidemia it was observed that total cholesterol levels were highest among 
anovulatory PCOS women (mean 189 mg/dL), followed by ovulatory PCOS women (mean 
178 mg/dL), and controls (166 mg/dL).133  After adjustment for age and BMI, the 35 women 
in our study with anovulatory cycles demonstrated a lipid profile more atherogenic than those 
224 women with two consecutive ovulatory cycles, though not to the extent often reported 
for women with ‘classic’ PCOS.  The latter is likely a consequence of our strict study 
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inclusion/exclusion criteria which was intended to exclude women at high risk or diagnosed 
with PCOS.  In fact, lipoprotein cholesterol levels (as well as glucose, insulin, HOMA-IR, 
and LH:FSH ratio) among the anovulatory women in our study were of the same range as 
healthy controls in other studies of PCOS when the age and BMI ranges were similar,133, 145, 
148-150
  although much lower than control groups age and/or BMI-matched to older, obese 
PCOS women.146  
Not all previous studies observed a more atherogenic lipid profile among PCOS 
women,150, 151  and differences could be due to small sample sizes, or differences in 
diagnostic criteria for classifying PCOS as there has been much debate regarding the 
diagnostic criteria for PCOS.152  It is interesting to note that while lipoprotein cholesterol 
levels among women with PCOS typically remain in the normal range according to the 
National Cholesterol Education Program criteria,119 women with PCOS have an increased 
risk of cardiovascular events.153, 154  We also did not observe a significant decrease in HDL 
cholesterol that many previous studies have noted.145, 147, 148, 151  This could be due in part to 
the fact that the full metabolic disturbances may not be present in the absence of obesity, and 
the women in our study were mostly of normal weight.133   
Based on the PCOS literature, a more atherogenic lipid profile would be expected 
among women with ovulatory disorders.144-148  These previous studies however were case-
control studies by design, and unable to prospectively evaluate the effects of lipoprotein 
cholesterol on anovulation and rule out the possibility of reverse causality.  In our 
prospective study we did not observe an association between baseline lipoprotein cholesterol 
levels and anovulation.  However, when we considered levels prior to the time of expected 
ovulation, total cholesterol was weakly associated with anovulation in that cycle.  After 
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adjusting for age at menarche and the LH:FSH ratio this result was attenuated towards the 
null. The fact that we did not observe associations between baseline lipoprotein cholesterol 
and anovulation could be due to the small number of anovulatory cycles in this study which 
limited statistical power, or to the limited range of lipoprotein cholesterol levels by inclusion 
of only healthy, regularly menstruating women.   
Through multiple sensitivity analyses, we sought to determine whether the weak 
association we observed between total cholesterol levels and anovulation could be due to 
underlying endocrine disturbances.  First, we adjusted our results for several different 
markers of endocrine function (LH:FSH ratio, current acne, hirsutism score, SHBG, insulin, 
HOMA-IR), in order to control for possible confounding by underlying endocrine 
disturbances.  The results of the associations between lipoprotein cholesterol levels and 
anovulation adjusting for the LH:FSH ratio and other markers were essentially the same 
(Table 6.3).  The fact that the results did not change after adjustment might suggest that these 
findings are not fully explained by underlying endocrine disturbances.  However we cannot 
rule out this possibility as the LH:FSH ratio, and the other markers we measured, are not 
perfect proxies for these conditions.  In addition, we did not have ultrasound test results to 
detect presence of polycystic ovaries or other more diagnostic criteria. 
Second, in order to further account for the effect of both measured and unmeasured 
chronic factors (age, BMI, underlying PCOS, and other unmeasured chronic factors), we did 
a paired analysis of the 23 women in our study for which we had day 2 lipoprotein 
cholesterol levels during both an ovulatory and anovulatory cycle.  In these comparisons, 
each woman was essentially matched to herself (i.e., case-crossover study), thus controlling 
by design for age, age at menarche, BMI, underlying PCOS, and any other factor that does 
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not vary over time, even those that went unmeasured.  On average, lipoprotein cholesterol 
levels were higher preceding the anovulatory cycle, and 16 of the 23 women (70%) had 
higher day 2 lipoprotein cholesterol levels preceding their anovulatory cycle.  This did not 
seem to be affected by time ordering of the cycles in that we observed higher levels whether 
the anovulatory cycle preceded the ovulatory cycle or vice versa.  It remains an alternative 
possible explanation to the findings that there is a time-varying effect that is driving these 
associations, however we observed similar results after adjusting for several factors that may 
change over time, such as glucose, insulin, SHBG, and the LH:FSH ratio (Figure 6.2).  
Androgen levels were not measured in this study though and could potentially account for 
some of this association.  These results are again suggestive of an association between 
lipoprotein cholesterol levels and anovulation that is independent of underlying endocrine 
disturbances, but are not conclusive.   
In addition to raised lipoprotein cholesterol levels, we also observed that the 
anovulatory women in our study displayed several characteristics of mild hyperandrogenism 
and other endocrine disturbances, although assessment of hyperandrogenemia was limited in 
our study as we did not measure androgen levels.  Phenotypically, self-reported hirsutism 
score assessments based on a modified Ferriman-Gallwey scale with 5 sites140 were not 
different between anovulatory and ovulatory women, but the prevalence of current acne 
increased with number of anovulatory cycles observed.  Moreover, anovulatory women in 
this study demonstrated higher levels of several non-specific markers for androgen 
bioactivity including higher LH:FSH ratios,155 higher follicular phase LH,156 and lower 
SHBG levels,157 all consistent with, but not diagnostic of, hyperandrogenism.  Increased 
LH:FSH ratios are indicative of hypothalamic-pituitary-ovarian dysfunction, which is 
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characteristic among women with PCOS.  In addition, insulin levels were increased to a 
small degree among anovulatory women, an observation consistent with the insulin 
resistance that frequently accompanies PCOS.158     
To investigate these associations further, we evaluated whether these endocrine 
parameters characteristic of PCOS were significant predictors of sporadic anovulation 
adjusting for lipoprotein cholesterol levels.  We found that increased levels of day 2 LH:FSH 
ratio and acne, and reduced levels of day 2 SHBG were predictive of anovulation in a given 
cycle.  We also observed day 2 insulin levels to be a significant predictor only of LDL levels, 
although in all cases elevated day 2 insulin levels were associated with an increased risk of 
anovulation.  These findings raise the possibility of a very mild phenotype of PCOS among 
our anovulatory women.  More research is needed to identify the pathophysiology of incident 
anovulation, particularly in the context of the spectrum of PCOS.  The variability that we 
observed in gonadotropin and hormone secretion patterns even among a group of women 
reporting ‘regular’ menstrual cycles further emphasizes the need for additional research into 
risk factors for anovulation in larger populations of premenopausal women.  
To our knowledge this is the first study to prospectively evaluate the association 
between baseline lipoprotein cholesterol levels, and lipoprotein cholesterol levels prior to the 
time of expected ovulation, and anovulation.  By preserving temporality we were able to 
further evaluate whether the associations we observed could be due to biological effects of 
lipoprotein cholesterol on anovulation, rather than just being symptomatic of an underlying 
condition which leads to both ovulatory dysfunction and a more atherogenic lipid profile.  In 
addition, we were also able to evaluate the possibility of confounding by underlying 
endocrine disturbances by adjustment for several markers of endocrine function.  Through 
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the use of weighted generalized linear mixed models, we were also able to take into account 
the effects of varying reproductive hormone levels over the cycle.  This study is further 
distinguished from previous research by its strict inclusion/exclusion criteria to include a 
group of normally menstruating women with no diagnosed cases of PCOS.   
While this study allowed us to expand upon previous studies in this area, we were 
limited by a small number of anovulatory cycles, and an imperfect measurement of 
ovulation.  The small number of anovulatory cycles was partly a consequence of our 
employment of a conservative definition for anovulation, and limited the power we had to 
detect effects.  This could partially explain why we did not observe significant associations 
between lipoprotein cholesterol levels and anovulation.  While we did have multiple serum 
hormone measurements to aid in classifying ovulation, along with the use of fertility 
monitors measuring LH daily in urine, daily measures of progesterone and transvaginal 
ultrasounds (the gold standard) were not available, and thus misclassification of ovulation is 
possible.  However, a sensitivity analysis to evaluate misclassification of ovulation using a 
less conservative definition of anovulation was performed and yielded similar results.  We 
were also unable to directly measure androgen levels, and had to rely on several non-specific 
markers.  In particular, the hirsutism questionnaire used in this study was based on only 5 
sites and has not been previously validated, and cannot be directly compared with results 
from previous studies.  As this was a study among women reporting regular menstrual cycles 
with no history of PCOS, we have no ultrasound examinations for presence of polycystic 
ovaries.   
 In conclusion, we observed that women with at least one anovulatory cycle tended to 
display a more atherogenic lipid profile, along with several characteristics consistent with 
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mild hyperandrogenism.  This is the first study to prospectively evaluate the effects of 
lipoprotein cholesterol levels leading up to ovulation and anovulation, while taking into 
account possible effects due to underlying PCOS by design and by analysis.  While we 
observed a weak association between total cholesterol and anovulation, this association 
became non significant after adjustment for age at menarche and several markers of 
endocrine function.  However, we did find that the LH:FSH ratio, SHBG, current acne, and 
insulin levels were predictors of incident anovulation among regularly menstruating women.  
Collectively, these markers are consistent with a small degree of hyperandrogenism and may 
be indicative of a mild undiagnosed PCOS phenotype.  Further prospective studies are 
needed to elucidate the biological mechanisms that lead to sporadic anovulation and mild 
PCOS. 
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F. Tables and Figures 
Table 6.1.  Baseline demographic characteristics and lipoprotein cholesterol levels of women 
enrolled in the BioCycle study by ovulatory status (n=259). 
 
Overall              
Women 
Number of Anovulatory Cycles 
0 1 2 
 
  n=259 n=224 n=28 n=7 p value* 
Demographics          
Age, yrs: mean ± SD 27.3 ± 8.2 28.0 ± 8.3 23.2 ± 6.1 19.4 ± 0.9 0.0004 
BMI, kg/m2: mean ± SD 24.1 ± 3.9 24.2 ± 3.9 23.8 ± 4.0 21.6 ± 2.1 0.21 
Cycle 1 length, days: mean ± SD 28.9 ± 4.6 29.0 ± 4.5  30.0 ± 5.3 24.4 ± 2.6 0.02 
Cycle 2 length, days: mean ± SD 28.7 ± 3.5 28.8 ± 3.2 29.1 ± 5.7 25.7 ± 3.1 0.09 
Physical Activity: n (%)         0.75 
Low 25 (9.7) 22 (9.8) 2 (7.1) 1 (14.3)  
Moderate 92 (35.5) 81 (36.2) 8 (28.6) 3 (42.9)  
High 142 (54.8) 121 (54.0) 18 (64.3) 3 (42.9)  
Race: n (%)         0.92 
White  154 (59.5) 134 (59.8) 15 (53.6) 5 (71.4)  
Black 51 (19.7) 43 (19.2) 7 (25.0) 1 (14.3)  
Other 54 (20.9) 47 (21.0) 6 (21.4) 1 (14.3)  
≤ High school education: n (%) 33 (12.7) 29 (13.0) 2 (7.1) 2 (28.6) 0.28 
Current smoker: n (%) 10 (3.9) 9 (4.0) 0 (0.0) 1 (14.3) 0.22 
Married: n (%) 66 (25.5) 65 (29.0) 1 (3.6) 0 (0.0) 0.002 
Nulliparous: n (%) 187 (73.9) 154 (70.0) 26 (100.0) 7 (100.0) 0.0002 
Past OC Use: n (%) 140 (54.9) 127 (57.2) 11 (42.3) 2 (28.6) 0.14 
Age at menarche, yrs: mean ± SD 12.5 ± 1.2 12.4 ± 1.2 12.5 ± 1.4 13.1 ± 1.5 0.32 
Years since menarche: mean ± SD 14.9 ± 8.3 15.7 ± 8.3 10.5 ± 6.9 6.3 ± 1.5 0.0002 
Baseline Lipoprotein Cholesterol Levels (mg/dL)†       
Total Cholesterol: mean ± SD 163.4 ± 29.0 163.6 ± 29.6 163.1 ± 26.2 158.1 ± 22.2 0.92 
Adjusted for age, BMI‡   
162.8  
(159.1, 166.5) 
167.2  
(156.5, 177.9) 
167.9  
(146.8, 188.9) 0.69 
HDL Cholesterol: mean ± SD 50.1 ± 11.5 50.0 ± 11.7 50.0 ± 10.7 51.4 ± 9.5 0.91 
Adjusted for age, BMI   
50.0  
(48.5, 51.5) 
50.5  
(46.2, 54.8) 
50.9  
(42.4, 59.4) 0.96 
LDL Cholesterol: mean ± SD 101.5 ± 25.7 101.7 ± 26.0 101.1 ± 24.2 96.3 ± 22.4 0.75 
Adjusted for age, BMI   
101.1  
(97.8, 104.4) 
104.2  
(94.8, 113.7) 
102.9  
(84.2, 121.6)  
Triglycerides: mean ± SD 59.2 ± 27.9 59.0 ± 27.8 60.1 ± 30.8 62.3 ± 20.3 0.83 
Adjusted for age, BMI     
58.5  
(54.9, 62.0) 
62.4  
(52.1, 72.7) 
70.6  
(50.2, 90.9) 0.43 
BMI, body mass index; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; OC, 
oral contraceptives; SD, standard deviation 
*p value for continuous variables calculated using ANOVA, and for categorical variables using Fisher's exact test. 
†Baseline levels were measured at the first visit of the first cycle (day 2 of menses). 
  
‡Values are predicted means (95% CI) after adjusting for age and BMI.         
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Table 6.2.  Markers of endocrine function among women in the BioCycle study (n=259). 
    Number of Anovulatory Cycles† 
 Overall* 0 1 2  
  n=259 n=224 n=28 n=7 
p 
value‡ 
Hirsutism score 3.03 ± 2.58 3.02 (2.68, 3.36)** 3.24 (2.26, 4.21) 2.43 (0.49, 4.38) 0.76 
      
Currently have acne: n(%)§ 72 (30.5) 58 (28.4) 9 (36.0) 5 (71.4) 0.04 
      
Waist-to-Hip Ratio 0.75 ± 0.05 0.75 (0.75, 0.76) 0.76 (0.74, 0.79) 0.74 (0.68, 0.80) 0.67 
      
LH:FSH Ratio      
Day 2 0.61 ± 0.44 0.61 (0.57, 0.65) 0.86 (0.71, 1.03) 0.92 (0.64, 1.33) 0.0008 
Day 7 0.71 ± 0.47 0.71 (0.67, 0.75) 0.88 (0.75, 1.04) 0.92 (0.66, 1.28) 0.03 
Average of day 2 and day 7 0.70 ± 0.45 0.67 (0.64, 0.71) 0.93 (0.79, 1.09) 0.93 (0.67, 1.27) 0.0003 
      
SHBG nmol/L: Day 2  44.50 ± 29.05 45.07 (42.56, 47.73) 37.07 (31.47, 43.68) 28.27 (20.35, 39.27) 0.004 
      
Glucose mg/dL: Day 2  87.00 + 7.00 87.31 (86.57, 88.05) 86.46 (84.35, 85.57) 86.12 (81.90, 90.35) 0.67 
      
Insulin uIU/mL: Day 2  6.00 + 4.50 5.79 (5.42, 6.18) 6.99 (5.80, 8.42) 6.49 (4.47, 9.43) 0.16 
      
HOMA-IR: Day 2 1.32 + 0.56 1.29 (1.21, 1.38) 1.49 (1.22, 1.81) 1.43 (0.97, 2.13) 0.39 
FSH, follicle-stimulating hormone; HOMA-IR, homeostatic metabolic assessment to predict insulin resistance; LH, luteinizing 
hormone; SHBG, sex-hormone binding globulin 
*Values are mean ± SD for overall population. 
†Values are predicted means (95% CI) after adjusting for age and BMI.  LH:FSH ratio, SHBG, Insulin, and HOMA-IR are geometric 
means. 
‡p value for continuous variables calculated using ANOVA, for acne calculated using a chi-square test. 
§Acne: 5 or more pimples, pustules, or nodules on the face (except nose) during the last 3 months. 
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Table 6.3.  Results of weighted non-linear mixed effects models of the association between 
lipoprotein cholesterol levels preceding predicted ovulation and incident anovulation among 
women in the BioCycle study (n=259). 
    
Baseline lipoprotein cholesterol 
levels and anovulation*   
Levels of lipoprotein cholesterol 
up to predicted time of ovulation 
and anovulation† 
  OR 95% CI p-value  OR 95% CI p-value 
Total Cholesterol per 5 mg/dL      
 Model 1‡ 1.04 (0.97, 1.12) 0.27  1.09 (1.01, 1.17) 0.03 
 Model 2§ 1.03 (0.95, 1.11) 0.51  1.07 (0.99, 1.15) 0.09 
 Model 3║ 1.02 (0.95, 1.11) 0.56  1.07 (0.99, 1.16) 0.07 
HDL Cholesterol per 5 mg/dL      
 Model 1 1.02 (0.86, 1.20) 0.86  1.03 (0.87, 1.22) 0.71 
 Model 2 1.01 (0.85, 1.19) 0.92  1.02 (0.86, 1.20) 0.86 
 Model 3 1.01 (0.85, 1.20) 0.90  1.02 (0.86, 1.20) 0.86 
LDL Cholesterol per 5 mg/dL      
 Model 1 1.03 (0.95, 1.12) 0.42  1.07 (0.98, 1.16) 0.13 
 Model 2 1.02 (0.94, 1.11) 0.66  1.05 (0.96, 1.14) 0.28 
 Model 3 1.02 (0.94, 1.11) 0.60  1.04 (0.95, 1.13) 0.39 
Triglycerides per 5 mg/dL       
 Model 1 1.06 (0.99, 1.14) 0.10  1.04 (0.99, 1.10) 0.09 
 Model 2 1.05 (0.97, 1.13) 0.23  1.04 (0.99, 1.09) 0.16 
 Model 3 1.01 (0.93, 1.10) 0.76  1.04 (0.99, 1.10) 0.16 
                  
BMI, body mass index; FSH, follicle-stimulating hormone; HDL, high-density lipoprotein 
cholesterol; LDL, low-density lipoprotein cholesterol; LH, luteinizing hormone; OR, odds ratio; 
SD, standard deviation 
*Baseline levels of lipoprotein cholesterol levels were measured on day 2 of menses during the 
first cycle under study.  These models evaluate the association between baseline lipoprotein 
cholesterol and anovulation using generalized linear mixed models. 
‡Levels of lipoprotein cholesterol were allowed to vary up to the time of predicted ovulation, 
and included up to 4 measurements per woman per cycle.  These models evaluate the 
association between lipoprotein levels preceding ovulation and anovulation in that cycle using 
weighted generalized linear mixed models. 
‡Model 1 is adjusted for age, BMI, fiber intake, and total energy.  In weighted models for the 
association of lipoprotein cholesterol levels up the predicted time of ovulation, models also 
adjusted for levels of other reproductive hormones.  Measurements taken on day 2 of menses are 
considered to be unaffected by other hormone levels. 
§Model 2 adjusts for age at menarche in addition to the covariates included in Model 1. 
║Model 3 adjusts for LH:FSH ratio on day 2 in addition to the covariates included in Model 2. 
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Figure 6.1.  Odds ratios and 95% confidence intervals for associations between endocrine 
factors and risk of anovulation adjusted for total cholesterol, age, age at menarche, BMI, 
fiber intake, and total energy. 
 
 
FSH, follicle stimulating hormone; HOMA-IR, homeostatic metabolic assessment to predict 
insulin resistance; LH, luteinizing hormone; SHBG, sex-hormone binding globulin  
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Figure 6.2.  Odds ratios and 95% confidence intervals for day 2 lipoprotein cholesterol levels 
and anovulation in 23 women experiencing an ovulatory and anovulatory cycle during the 
study period; models unadjusted and adjusted for LH:FSH ratio. 
 
HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol 
VII. Dissertation Manuscript #3:  Direct Effects of Dietary Fiber Intake on Lipoprotein 
Cholesterol Levels in Premenopausal Women 
A. Abstract 
High fiber diets are associated with the lowering of lipoprotein cholesterol levels.  It 
has been hypothesized that estrogen could potentially mediate this effect in premenopausal 
women. Healthy, regularly menstruating women enrolled in the BioCycle study were 
followed for up to 2 menstrual cycles (n=259), with lipoprotein cholesterol and hormone 
levels measured in serum at up to 16 points, with clinic visits timed using fertility monitors.  
Marginal structural models with inverse probability of exposure weights were used to 
estimate the controlled direct effect of fiber on lipoprotein cholesterol in premenopausal 
women when controlling for time dependent estrogen set at specific levels.  We observed 
reductions in total and LDL cholesterol and triglycerides, not mediated through estrogen, 
among women consuming only at or above 22 g/day, when controlling for estrogen at 
specified levels in the population (corresponding to oral contraceptive use and 
postmenopausal levels).  The controlled direct effects of fiber intake were reduced at higher 
estrogen levels, suggesting that estrogen mediates the association between fiber and 
lipoproteins by slightly diminishing the effect.  While the controlled direct effects we 
observed were not of clinical significance, these results provide further insights regarding the 
possible biological mechanisms of the effects of fiber on lipoprotein cholesterol, and support 
the hypothesis of a direct effect of fiber on cholesterol that might work through bile acid 
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metabolism.  More research is needed to elucidate these mechanisms among premenopausal 
women.  
 
B. Introduction 
Diets with increased fiber intake are recommended due to the many health promoting 
benefits associated with high fiber consumption.15, 159  In particular, evidence from 
randomized controlled trials, observational studies, and animal models, have all shown that 
dietary fiber lowers cholesterol and lipoprotein levels,15-17, 159, 160 which are common risk 
factors for cardiovascular disease (CVD).15, 89, 90, 159, 160  These overall decreases in total 
cholesterol are usually attributed to a reduction in low density lipoprotein (LDL) cholesterol, 
as high density lipoprotein (HDL) and triglyceride levels have not shown similar effects.   
However, there is also evidence that pre-and post-menopausal women respond 
differently to fiber intake,18, 19 with premenopausal women showing smaller reductions in 
lipoprotein cholesterol levels in response to fiber intake.  It has therefore been hypothesized 
that estrogen could potentially mediate the effect of fiber on lipoprotein cholesterol levels in 
premenopausal women.  High fiber intake has been associated with lower levels of 
estradiol,20-27 a result also confirmed in the BioCycle study in premenopausal women.28  
Since estrogen and lipoproteins are intrinsically linked, as estrogen stimulates lipoprotein 
metabolism and cholesterol is the precursor for steroidogenesis, the implications of fiber’s 
association with estrogen on lipoprotein metabolism is evident.  To date, however, there has 
been little research on how much of the observed effect of fiber on lipoprotein cholesterol 
levels is working directly, and not mediated by estrogen.   
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Therefore, the objective of this study was to determine the controlled direct effect of 
dietary fiber intake on lipoprotein cholesterol levels, among healthy, regularly menstruating 
women in the BioCycle study.  As high fiber diets continue to be endorsed by the leading 
dietary and public health associations, a better understanding of the direct and indirect effects 
of fiber intake on lipoprotein cholesterol levels is essential.  This knowledge could provide 
further insight regarding possible mechanisms, as well as valuable knowledge for the 
interpretation of studies of fiber intake among women of reproductive age.   
 
C. Methods 
Study Sample   
The BioCycle study was a prospective cohort of 259 women who were followed for 
one (n=9) or two (n=250) cycles.116  Participants were recruited from healthy premenopausal 
volunteers aged 18 to 44 from the western New York region.  Exclusion criteria included 
current use of oral contraceptives, vitamin and mineral supplements, or other medications 
including lipid lowering drugs, anti-hypertensive medications, and/or aspirin, pregnancy in 
the last 6 months, a recent history of infections or diagnosis of chronic conditions, including 
history of menstrual and ovulation disorders and gastrointestinal conditions (e.g. Crohn’s 
Disease).  Women with a self- reported body mass index (BMI) at screening less than 18 or 
greater than 35 were excluded, as were women planning to restrict their diet for weight loss 
or medical reasons.  Full details on inclusion and exclusion criteria have been reported 
elsewhere.116  The University at Buffalo Health Sciences Institutional Review Board 
approved the study and all participants provided written informed consent. 
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Data Collection 
The study involved 5 to 8 clinic visits per cycle (94% of all women completed at least 
7 visits per cycle) for up to 2 cycles, with visits timed using fertility monitors (Clearblue® 
Easy Fertility Monitor, Inverness Medical, Waltham, MA, USA) so that biospecimen 
collection occurred during specific phases of the menstrual cycle.  Monitors measured 
estrone-3-glucuronide and LH in urine daily starting on the 6th day following the start of the 
woman’s menstrual cycle.  Monitor indications of low, high, and peak fertility were used to 
time mid-cycle visits.  This new technology was used to accurately define menstrual cycle 
phase, representing a significant improvement over previous studies.135  Visits corresponded 
to biologically relevant windows including menstruation, mid- and late-follicular phase, 
luteinizing hormone (LH) and follicle stimulating hormone (FSH) surge, ovulation, and 
early-, mid-, and late-luteal phase.  
 
DietaryAssessment   
Dietary intake was assessed on the same days as sample collection using the 24-hour 
dietary recall methodology.  Recalls were conducted 4 times per cycle, for a total of up to 8 
recalls, using the Nutrition Data System for Research (NDSR) software version 2005 
developed by the Nutrition Coordinating Center (NCC), University of Minnesota, 
Minneapolis, MN. This program computed the nutrients (i.e. total energy, vitamin E) and 
non-nutrients (i.e. dietary fiber) from each day of intake. The majority of women completed 
4 dietary recalls per cycle (87%).  
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Hormone Assessment   
Estradiol, progesterone, LH, and FSH were measured in fasting serum samples 
collected at each visit.  Fasting morning blood draws were collected between 7:00 a.m. and 
8:30 a.m. at each visit and processed according to standardized protocols.136  Samples were 
frozen at -80oC and sent as complete participant cycle batches to the Kaleida Health Center 
for Laboratory Medicine (Buffalo, NY) for analysis of hormone concentrations.  Estradiol 
was measured using a radioimmunoassay.  Progesterone, LH, and FSH were measured using 
a solid phase competitive chemiluminescent enzymatic immunoassay by Specialty 
Laboratories, Inc. (Valencia, CA) on the DPC Immulite®2000 analyzer (Siemens Medical 
Solutions Diagnostics, Deerfield, IL).  The analytical imprecision of these assays was 
monitored using 3-level quality control (QC) materials as part of the laboratory’s quality 
assurance program.  Across the study period, the imprecision of all three QC material levels 
was <5% inter-assay coefficient of variation (%CV) for estradiol, LH, and FSH, and <10% 
CV for progesterone. 
 
Lipoprotein Assessment   
A complete lipid profile was performed for each cycle visit.  The lipid profile 
included analysis of total cholesterol, HDL cholesterol, and triglycerides, and was measured 
using a Beckman LX20 automated chemistry analyzer at the Kaleida Center for Laboratory 
Medicine (Buffalo, NY).  LDL cholesterol was determined indirectly using the Friedewald 
formula.84  The analytical imprecision across the study period was < 5% CV for all lipid and 
lipoprotein assays.   
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Covariate Assessment   
Participants were asked to complete questionnaires on lifestyle (smoking status), 
physical activity (International Physical Activity Questionnaire long form 2002),117 and 
reproductive history.  High, moderate, and low physical activity categories were formed 
based on standard IPAQ cut points.  Cycle length was defined as the number of days from the 
first day of bleeding (menstruating by 4:00 p.m.) until the day before the next onset of 
bleeding.  Physical and anthropometric measures were done according to standardized 
protocols and included height and weight, which were used to calculate BMI.  All covariates 
assessed had at least a 95% response rate. 
 
Controlled Direct Effects 
A simple directed acyclic graph (DAG) in Figure 7.1 displays the direct effect of fiber 
on lipoprotein cholesterol, and the indirect effect of fiber on lipoprotein cholesterol working 
through estrogen.161  Additionally, the hypothesized confounders of the fiber-lipoprotein 
association, the fiber-estrogen association, and the estrogen-lipoprotein association are also 
displayed.  In this analysis we are interested in estimating controlled direct effects, which are 
the direct effects when setting estrogen to a given level, and by so doing effectively blocking 
the effects of fiber on estrogen (and any other effects on estrogen), as is shown in Figure 7.1.  
The proposed methods assume that we can intervene on the mediator (estrogen) and change 
the value of estrogen, so that direct effects can be estimated at given levels of estrogen (i.e. 
controlled direct effects).  In theory there are as many direct effects as there are levels of 
estrogen.  Here we considered the controlled direct effects where estrogen is set to the mean 
level among postmenopausal women (11 pg/mL, equivalent to intervening and performing a 
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hysterectomy),162 and the mean level among premenopausal women on oral contraceptives 
(45 pg/mL, equivalent to intervening and giving women oral contraceptives).163, 164  
Controlled direct effects are to be distinguished from natural direct effects which block the 
effect of fiber on estrogen, but allow estrogen levels to vary among individuals because the 
effect of other factors on estrogen are not blocked.161, 165 
 
Statistical Analysis   
Descriptive statistics were computed for all study variables and exact chi-square tests 
and analysis of variance (ANOVA) were used to test for associations between demographic 
variables and levels of fiber intake, while taking into account multiple cycles per woman.  
Average levels of hormones across the cycle (estrogen, LH, FSH), average luteal phase 
progesterone, and baseline lipoprotein cholesterol levels (second day of menses during the 
first cycle under observation) were compared across levels of fiber intake using repeated 
measures ANOVA with Bonferroni adjusted comparisons.  No significant differences were 
found in dietary fiber intakes across each cycle, therefore the average daily intake of fiber 
was calculated per cycle.28  Fiber intake was categorized into multiple groups of equal size 
and compared using linear mixed models adjusted for age, BMI, and energy intake to 
determine whether there was evidence of a threshold effect of fiber intake.  Fiber intake was 
subsequently categorized according to whether a woman consumed at or above 22 g/day.  
Predicted mean levels of hormones and lipoproteins were calculated for each visit by fiber 
intake after adjusting for age, BMI, and total energy, using linear mixed models with random 
intercepts. 
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 Marginal structural models (MSMs) with inverse probability of exposure weights 
were applied to estimate the controlled direct effect of fiber intake on lipoprotein levels.165  
Weighted linear mixed effects models were used to model the association, allowing 
lipoprotein levels to vary over time, and treating fiber intake as a dichotomous variable 
indicating whether the woman consumed at or above 22 g/day during each cycle.  Stabilized 
weights were obtained by estimating two sets of weights, one for fiber intake and one for 
estrogen levels.  Weights for dichotomous fiber intake were obtained by logistic regression, 
and for continuous estrogen levels by linear regression replacing the probabilities with values 
from a probability density function.115  Weight models included age, BMI, energy intake, 
physical activity, vitamin E, LH, and FSH levels (see Figure 7.1).  Confidence intervals were 
bootstrapped.165   
Further, we also evaluated the effects of meeting the daily reference intake (DRI) of 
fiber intake on lipoprotein cholesterol levels, with the DRI based on the Institute of 
Medicine’s recommendation of 14 grams of fiber per day per 1,000 kcal.105  We calculated a 
woman’s individual DRI for fiber intake based on her estimated total energy intake from the 
24-hour recall, as well as based on her estimated energy requirements according to her age, 
weight, and height.  Fiber intake was then categorized as at or above the individual DRI for 
each woman.  SAS version 9.1 (SAS Institute, Cary, NC, USA) was used for all statistical 
analyses.   
 
D. Results 
The distribution of demographics, hormone levels, baseline lipoprotein levels, and 
dietary factors by fiber intake are displayed in Table 7.1.  Fiber intake above and below 22 
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g/day varied significantly according to age and race/ethnicity, with younger and minority 
women tending to consume less fiber.  BMI and physical activity were not significantly 
associated with fiber intake.  Average estrogen levels across the cycle, and average luteal 
phase progesterone levels were lower among women consuming at or above 22 g/day.  
Baseline total and LDL cholesterol, and triglyceride levels were lowest among women 
consuming at or above 22 g/day.  There were no significant differences in HDL cholesterol 
levels between fiber intake categories.  Analysis of fiber intake according to quartiles of 
intake produced similar results for demographic and dietary characteristics (data not shown). 
Fiber intake was inversely associated with estrogen levels, as shown in Figure 7.2 
which displays the predicted means of estrogen concentrations according to fiber intake at 
each clinic visit across the menstrual cycle after adjusting for age, BMI, and total energy.  
Women consuming at or above 22 g/day had lower mean estrogen levels across the cycle, as 
well as lower luteal phase progesterone, and a lower LH peak (Figure 7.2).  There were no 
differences in FSH levels across the cycle by fiber intake category.  Women consuming at or 
above 22 g/day also displayed lower total and LDL cholesterol across the cycle.  Triglyceride 
levels were lower during menses, the follicular phase, and around the time of expected 
ovulation (Figure 7.3.  No consistent pattern was noticed for HDL cholesterol. 
Women consuming at or above 22 g/day were observed to have significantly lower 
total and LDL cholesterol levels using linear mixed models, with evidence of a threshold 
effect of fiber intake (data not shown).  When fiber intake was grouped into quantiles 
(tertiles, quartiles, quintiles, 8, 10, 12, 15), we only observed significant associations between 
high fiber intake and total and LDL cholesterol levels when the cut point for creation of the 
highest category was above 21.8 g/day pointing to a possible threshold effect.  In particular, 
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the highest category was significantly different from each of the other categories of lower 
intake, with no differences in lipoprotein cholesterol level between the lower categories.  
Fiber intake was not significantly associated with HDL cholesterol or triglycerides.   
 Using MSMs, the controlled direct effects of fiber intake (≥ 22 versus < 22 g/day) on 
lipoprotein cholesterol levels were statistically significant for total and LDL cholesterol and 
triglycerides (Table 7.2).  In other words, high fiber intake had a significant controlled direct 
effect on lowering lipoprotein cholesterol levels when setting estrogen at levels 
corresponding to levels of women on oral contraceptives, and to levels of postmenopausal 
women.  High fiber intake did not have a controlled direct effect on HDL cholesterol.  The 
controlled direct effects were small, and consuming fiber above 22 g/day was only associated 
with a decrease in lipoprotein cholesterol levels of about 1 mg/dL on average.  The controlled 
direct effect of fiber intake on total cholesterol was significant at low levels of estrogen, but 
only marginally significant at high estrogen levels.  Controlled direct effects on LDL were 
consistent at both levels of estrogen evaluated, whereas effects on triglycerides were only 
significant at low levels of estrogen. 
We did not observe significant reductions in lipoprotein cholesterol levels in response 
to meeting the DRI of fiber intake based on either a woman’s estimated total energy intake 
from the 24-hour recall, or her estimated energy requirements according to her age, weight, 
and height (data not shown).  We observed a wide range of energy intakes in this population 
(515 to 3717 kcal), corresponding to DRI’s of fiber intake between 7 and 52 g/day.  
Estimated energy requirements based on the Mifflin criteria averaged 1378 kcal, with a range 
of 1093 to 1819 kcal, corresponding to DRI’s of fiber intake between 15 and 26 g/day).166, 167  
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E. Discussion 
 We found that fiber consumption only at or above 22 g/day was associated with lower 
total and LDL cholesterol and triglyceride levels, independent of estrogen, when estrogen 
was set at levels corresponding to levels of women on oral contraceptives, and levels of 
postmenopausal women.  While high fiber intakes were associated with reduced levels of 
total and LDL cholesterol and triglycerides, the controlled direct effect was reduced at higher 
levels of estrogen.  These results suggest that estrogen mediates the association between fiber 
and lipoproteins by slightly decreasing the effect among premenopausal women.  The effects 
we observed were small and not clinically important, but do provide further insights 
regarding the possible biological mechanisms of the effects of fiber on lipoprotein 
metabolism, and suggest that fiber has an independent or direct effect on lowering lipoprotein 
cholesterol levels.   
The observed associations between high fiber intake and reduced total and LDL 
cholesterol levels are in line with several randomized controlled trials and observational 
studies that have found fiber intake to be associated with a less atherogenic lipid profile.15, 96, 
159, 168-170
  The effects of fiber intake on lipoprotein cholesterol levels are generally observed 
at high levels of intake.  In randomized controlled trials of fiber intake, supplementation was 
usually designed so that women would be consuming high amounts of fiber (generally 
greater than 20 g/day).  In observational studies, typically the highest quintile or the 4th and 
5th quintiles of fiber intake were associated with lower total cholesterol levels.168, 170  Cut 
points for these high levels of intake were similar to the threshold level we observed around 
22 g/day.  The apparent threshold association could be explained by the fact that fiber intakes 
in this population were low, and so we could only observe significant effects at high levels.  
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However, the fact that we observed no reductions in lipoprotein cholesterol levels for women 
meeting the DRI requirements also supports the presence of a threshold effect of fiber intake.  
In particular, when we evaluated the effects of meeting the DRI requirements, using 
approaches based on calculating a woman’s individual DRI from her estimated total energy 
intake from the 24-hour recall, or from her estimated energy requirements according to her 
age, weight, and height, we observed no reductions in lipoprotein cholesterol levels.  It seems 
that the effects of fiber intake on lowering lipoprotein cholesterol independent of estrogen 
levels are in response to high levels of intake, and not in response to meeting the 
recommendations or consuming a certain portion of fiber from the diet.  Even at high levels 
of fiber intake though the controlled direct effects we observed were small, and not of 
clinical importance (consuming at or above 22 g/day was only associated with a decrease of 
about 1 mg/dL).  It should be noted that the total effect of high fiber intake in this population 
was also low (only about 5 mg/dL).   
We also observed that the controlled direct effects of fiber on total cholesterol and 
triglycerides were reduced at high levels of estrogen, while the effects of fiber on LDL 
cholesterol were similar at both high and low levels of estrogen.  The controlled direct effects 
we estimated, however, assume that we can intervene and set the estrogen levels of all 
women in the population to a given value.  We chose to estimate controlled direct effects at 
the level of estrogen we would expect to see among postmenopausal women versus the level 
we would expect to see if we intervened and put all women on oral contraceptives.  While we 
did not directly compare pre- and post-menopausal women in this study, our findings are 
similar to studies comparing pre- and post-menopausal women that have observed reduced 
responses to fiber supplementation among premenopausal women.18, 19  In a study among 8 
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premenopausal and 11 postmenopausal women, psyllium fiber supplementation (15 g/day) 
significantly decreased total cholesterol levels from baseline among postmenopausal women, 
but not in premenopausal women.  Similarly, a crossover trial which included 23 
premenopausal and 21 postmenopausal women found that total cholesterol decreased 
modestly during the fiber period (3.8%) among postmenopausal women, but only by 0.6% 
among premenopausal women, although these differences were not significant.  While there 
were several important differences between this crossover trial and our study (i.e. older and 
more obese study population, trial evaluating fiber supplementation, and higher fiber intakes 
on average before supplementation), together these findings suggest that there are differences 
in the impact of fiber intake on lipoprotein cholesterol, potentially mediated by estrogen 
levels.  
The mechanisms involved in the reduction of serum cholesterol levels related to 
increased fiber intake support the presence of multiple pathways, with estrogen as a possible 
mediating factor.  Although the mechanisms remain somewhat inconclusive, the major direct 
mechanism of fiber’s effect on lipoprotein cholesterol levels is hypothesized to work through 
bile acid metabolism.171  Fiber decreases absorption of biliary cholesterol and bile acids, 
increases bile acid synthesis, and enhances fecal excretion of bile acids, thereby leading to a 
decrease in cholesterol levels.  However, as increased fiber intake does not always lead to an 
increased fecal output of bile acids, it has been suggested that the reduction in cholesterol 
levels may be working through another mechanism as well.111, 114  As an alternative, dietary 
fiber may act on cholesterol through altering serum hormone concentrations or short-chain 
fatty acids which could in turn affect lipid metabolism.111  As discussed, high fiber intakes 
have been associated with lower levels of estradiol,20-28 presumably due to a reduction in β-
 107 
 
glucuronidase activity in feces in response to fiber intake, which subsequently leads to a 
decline in the reabsorption of estrogen in the colon.107  As increased estradiol tends to have 
beneficial effects on the lipid profile,9-11 the reduction in estradiol in response to fiber intake 
would presumably lead to an increase in lipoprotein cholesterol levels.  This could potentially 
explain why we observed a decreased controlled direct effect of fiber intake on lipoprotein 
cholesterol at high levels of estrogen as compared with low levels. 
 To our knowledge this is the first study to evaluate the independent effects of fiber on 
lipoprotein cholesterol levels, and to estimate controlled direct effects (i.e. the effect of fiber 
when estrogen is set at specified levels—here corresponding to levels among women on oral 
contraceptives versus levels typically seen among postmenopausal women).  MSMs were 
used to estimate the controlled direct effects of fiber intake on lipoprotein cholesterol levels 
because they offer several important advantages over standard approaches.  Perhaps the most 
important advantages of the MSM approach are that MSMs can control for time-varying 
confounders affected by prior exposure, as well as accommodate interactions between fiber 
and estrogen.  First, MSMs adequately adjust for time-modified confounding caused by 
changing reproductive hormone levels during the menstrual cycle.  Second, standard 
approaches for effect decomposition are not valid in the presence of interactions, and would 
require that there be no women in the population where fiber had a causal effect on both 
estrogen and lipoprotein levels.172  Based on our knowledge of the effects of fiber on both 
estrogen and lipoproteins, absence of such an interaction seems biologically implausible.  
This is an especially important consideration, given that the use of standard methods would 
never be appropriate in this situation given the interaction between fiber and estrogen.  When 
such an interaction is present, the total effect cannot be partitioned into direct and indirect 
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effects using standard approaches and requires that additional assumptions be met when 
using MSMs.165, 172  Had we analyzed the association using the standard approach 
(comparing the effect estimate adjusted for potential confounders to an estimate adjusted for 
the same confounders plus the hypothesized mediating variable)173-175 we would not have 
observed any mediation by estrogen, and would have concluded only that fiber had a direct 
effect on lipoprotein cholesterol levels.  The BioCycle study offers a unique opportunity to 
apply these methods and to adjust for the effects of potential confounding by reproductive 
hormones due to the prospective, longitudinal nature of the study, with multiple measures of 
dietary intake, hormones, and lipoprotein cholesterol levels. 
Our analysis is restricted by the assumptions of MSMs which limit our interpretation 
of the effects.165  In estimating controlled direct effects we have assumed that we can 
intervene and set estrogen levels to be a certain value.  Although this is a possible 
intervention through the use of oral contraceptives, it is not necessarily a practical one.  In 
addition, MSMs assume positivity, in that the probabilities in the denominators of the 
weights cannot be zero, as well as no unmeasured confounding (i.e. exchangeability).115, 120, 
165, 176
  Specifically we assume no unmeasured confounding of the treatment-outcome 
relationship, and the mediator-outcome relationship, assumptions that are hard to verify in 
practice, but assumed in standard analysis methods as well.  Despite the fact that we had 
standardized assessments of a wide variety of participant and dietary characteristics which 
increased our ability to adjust for potential confounders, it is still possible that there is 
unmeasured confounding.  Our study sample population was restricted to healthy normally 
menstruating women in order to exclude potential confounders by design, but such 
restrictions could also limit the generalizability of our findings.  Although the average fiber 
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intake among women in this study was 13.6 g/day, which is comparable to the average fiber 
intake in the U.S. (13.8 g fiber/d for reproductive-aged women),105, 159 these intakes were 
substantially lower than the recommendations, and we were limited by observing only a 
small number of women consuming at or above 22 g/day.  In addition, follow-up was limited 
for two cycles, and fiber intake was based on estimates obtained from 24-hour recalls.   
In conclusion, we observed reductions in total and LDL cholesterol and triglycerides, 
not mediated through estrogen, only among women consuming at or above 22 g/day, when 
controlling estrogen at specified levels in the population corresponding to levels of women 
on oral contraceptives and among postmenopausal women.  The lipid-lowering effects of 
fiber intake were only observed at high levels of intake, indicating the importance of 
consuming a high amount of fiber.  The controlled direct effects of fiber intake were reduced 
at higher estrogen levels, suggesting that estrogen mediates the association between fiber and 
lipoproteins by slightly diminishing the effect.  Despite the reduced controlled direct effect of 
fiber on lipoproteins due to estrogen, high fiber consumption was independently associated 
with an improved lipid profile.  Similar approaches could be applied to determine the direct 
effects of other dietary factors that are also associated with estrogen levels (i.e. soy intake, fat 
intake).  While the controlled direct effects we observed were not of clinical significance, 
these findings add to the current understanding regarding the possible biological mechanisms 
of fiber’s effect on lipoproteins.  In addition, these results suggest that fiber has an 
independent effect on lowering lipoprotein levels that is partially mediated by estrogen, and 
support the hypothesis of a direct effect of fiber on cholesterol that might work through bile 
acid metabolism.  More research is needed to elucidate these mechanisms among 
premenopausal women. 
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F. Tables and Figures 
Table 7.1.  Characteristics of participants in the BioCycle study according to dietary fiber 
intake at or above 22 g/day (n=509 cycles). 
      Fiber Intake   
  Total Cohort < 22 g/day ≥ 22 g/day 
P-
value 
n (number of cycles) 509 468 41  
        
Demographics        
Age, yrs: mean (SD) 27.4 (8.2) 27.4 (8.3) 27.0 (8.0) 0.73 
BMI, kg/m2: mean (SD) 24.1 (3.9) 24.2 (3.8) 22.8 (4.3) 0.05 
Race: n (%)       0.04 
White  302 (59.3) 269 (57.5) 33 (80.5)  
Black 101 (19.8) 98 (20.9) 3 (7.3)  
Other 106 (20.8) 101 (21.6) 5 (12.2)  
≤ High school education: n (%) 65 (12.8) 63 (13.5) 2 (4.9) 0.29 
Married: n (%) 131 (25.7) 118 (25.2) 13 (31.7) 0.49 
Nulliparous: n (%) 367 (73.6) 336 (73.4) 31 (75.6) 0.81 
Current smoker: n (%) 20 (3.9) 20 (4.3) 0 (0.0) 1.00 
Physical Activity: n (%)       0.51 
Low 48 (9.5) 44 (9.4) 4 (9.8)  
Moderate 182 (36.0) 163 (34.8) 19 (46.3)  
High 275 (54.5) 261 (55.8) 18 (43.9)  
Past OC Use: n (%) 275 (54.7) 248 (53.7) 27 (65.9) 0.24 
        
Reproductive hormones, mean (SD)       
Average estradiol, pg/mL 112.3 (91.0) 114.4 (92.2) 87.4 (69.9) 0.00 
Average luteal progesterone, ng/mL 7.3 (5.5) 7.4 (5.5) 5.7 (4.9) 0.01 
Average LH, ng/mL 9.6 (11.6) 9.6 (11.7) 8.9 (10.6) 0.20 
Average FSH, mIU/mL 6.4 (4.2) 6.4 (4.2) 6.4 (4.4) 0.92 
        
Baseline lipoprotein cholesterol levels, mean (SD)     
Total cholesterol, mg/dL 163.4 (29.0) 164.7 (29.1) 147.5 (23.1) 0.01 
HDL cholesterol, mg/dL 50.1 (11.5) 50.1 (11.6) 50.1 (9.3) 0.86 
LDL cholesterol, mg/dL 101.5 (25.7) 102.6 (25.8) 87.6 (20.4) 0.01 
Triglycerides, mg/dL 59.2 (27.9) 60.1 (28.4) 48.6 (17.3) 0.08 
        
Dietary intake, mean (SD)        
Total energy, kcal 1608.1 (405.0) 1578.7 (390.0) 1943.3 (426.9) 0.00 
Total fiber, g/day 13.6 (6.0) 12.3 (4.0) 28.1 (5.6) <.0001 
Insoluble fiber, g/day 9.6 (4.7) 8.6 (3.1) 21.0 (4.6) <.0001 
Soluble fiber, g/day 3.8 (1.4) 3.5 (1.1) 6.8 (1.4) <.0001 
BMI, body mass index; FSH, follicle stimulating hormone; HDL, high density lipoprotein; LDL, low 
density lipoprotein; LH, luteinizing hormone; OC, oral contraceptives; SD, standard deviation. 
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Table 7.2.  Results of marginal structural models for estimating the controlled direct effect of 
fiber intake (≥ 22 g/day versus < 22) on log lipoprotein levels using weighted linear mixed 
effects models among women participating in the BioCycle study. 
  Estrogen levels* Estimate† 95% CI 
Total Cholesterol 
(mg/dL) Postmenopausal 11 pg/mL -0.060 (-0.106, -0.018) 
 Premenopausal 45 pg/mL -0.044 (-0.087, -0.012) 
     
HDL Cholesterol 
(mg/dL) Postmenopausal 11 pg/mL 0.000 (-0.047, 0.049) 
 Premenopausal 45 pg/mL 0.015 (-0.024, 0.052) 
     
LDL Cholesterol 
(mg/dL) Postmenopausal 11 pg/mL -0.068 (-0.130, -0.011) 
 Premenopausal 45 pg/mL -0.068 (-0.121, -0.028) 
     
Triglycerides 
(mg/dL) Postmenopausal 11 pg/mL -0.161 (-0.282, -0.031) 
 Premenopausal 45 pg/mL -0.069 (-0.158, 0.022) 
BMI, body mass index; CI, confidence interval; FSH, follicle stimulating hormone; LH, 
luteinizing hormone. 
*Controlled direct effects are calculated at a given level of estrogen; here we present 
controlled direct effects at mean postmenopausal and mean premenopausal levels of 
estrogen. 
†Estimates are adjusted for age, BMI, physical activity, total energy intake, vitamin E 
intake, LH, FSH through the use of inverse probability of exposure weights. 
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Figure 7.1.  Directed acyclic graph of the controlled direct effect of fiber intake on 
lipoprotein cholesterol which is estimated by setting estrogen levels to a fixed value and thus 
blocking all of the effects on estrogen.161 
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Figure 7.2.  Predicted mean levels of estradiol, progesterone, LH, and FSH across the menstrual cycle according to fiber intake at 
or above 22 g/day among women in the BioCycle study.  Predicted means are based on linear mixed effects models with random 
intercepts adjusted for age, BMI, and total energy. 
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Figure 7.3.  Predicted means levels of total, LDL, and HDL cholesterol, and triglycerides across the menstrual cycle according to 
fiber intake at or above 22 g/day among women in the BioCycle study.  Predicted means are based on linear mixed effects models 
with random intercepts adjusted for age, BMI, and total energy.  
 
  
 
VIII. CONCLUSIONS 
The purpose of this dissertation was to understand how the menstrual cycle interacts 
with other metabolic processes, specifically lipid metabolism.  In particular, we were 
interested in the effects of estrogen on lipid metabolism, the effects of baseline lipoprotein 
cholesterol levels on the risk of incident anovulation, and the direct effects of dietary fiber 
intake on lipoprotein cholesterol not mediated by estrogen.   
We observed that lipoprotein cholesterol levels varied across the menstrual cycle and 
were associated with endogenous estrogen levels, confirming the hypothesized beneficial 
effects of endogenous estrogen on lipoprotein cholesterol levels.  Our results also suggest 
that the effects of estrogen on lowering total and LDL cholesterol are not acute.  
We also found that the anovulatory women in our study displayed a more atherogenic 
lipid profile and endocrine characteristics indicative of hyperandrogenism.  While lipoprotein 
cholesterol levels were only weakly associated with the risk of anovulation, we identified 
several predictors of incident anovulation (the LH:FSH ratio, SHBG, insulin, and acne).  
These markers, along with sporadic anovulation, may be indicative of a mild undiagnosed 
PCOS phenotype even among women reporting ‘regular’ menstrual cycles.   
Dietary fiber intake was shown to have an independent effect on lipoprotein 
cholesterol levels, not mediated by estrogen.  Specifically, we observed a direct effect of 
fiber intake on reducing total and LDL cholesterol and triglycerides, among women 
consuming at or above 22 g/day, when setting estrogen at levels corresponding to levels of 
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women on oral contraceptives and among postmenopausal women.  The controlled direct 
effects of fiber intake were reduced at higher estrogen levels, suggesting that estrogen 
mediates the association between fiber and lipoproteins by slightly diminishing the effect.  
Despite the reduced controlled direct effect of fiber on lipoproteins due to estrogen, high 
fiber consumption was independently associated with an improved lipid profile at all levels 
of estrogen.   
This study is the first to evaluate the association between endogenous estrogen and 
lipoproteins using multiple longitudinal serum measures of estrogen and lipoproteins, while 
comprehensively considering potential impacts from other reproductive hormones.  More 
importantly, this research helps to fill an etiological gap in understanding the relationship 
between lipoprotein cholesterol changes induced by hormonal variations during the 
menstrual cycle.  Cyclic variations in lipoprotein cholesterol levels observed in the present 
study have potential clinical implications regarding the appropriate timing of lipoprotein 
cholesterol measurement during the menstrual cycle and may need to be accounted for in the 
design and interpretation of studies in women of reproductive age. In addition, this is the first 
study to our knowledge to prospectively identify endocrine markers of sporadic anovulation 
in a group of regularly menstruating women.  Further studies are needed to confirm these 
results and help elucidate the biological mechanisms that lead to sporadic anovulation in 
healthy women.  Understanding the factors associated with anovulation is important as 
anovulation might be associated with infertility.  Lastly, while the controlled direct effects of 
fiber intake on lipoprotein cholesterols were not of clinical significance, these findings add to 
the current understanding regarding the possible biological mechanisms of fiber’s effect on 
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lipoproteins, and suggest that fiber has an independent effect on lowering lipoprotein levels.  
More research is needed in this area to better understand the biological mechanisms. 
In conclusion, these findings provide insight into the complex associations between 
hormones and lipoproteins during the menstrual cycle, and how dietary factors affect these 
relationships.  Menstrual cycle phase should be considered in the design and interpretation of 
studies in women of reproductive age due to estrogen’s influence on many biological 
processes. 
 
A. Strengths 
The BioCycle study offered a rich and unique data source for better understanding the 
biological processes of the menstrual cycle, and for improved characterization of hormonal 
profiles, menstrual cycle characteristics, lipid profiles, and dietary intake across the cycle.  In 
particular, the BioCycle study consisted of multiple serum measurements of both hormone 
and lipoprotein cholesterol levels across two menstrual cycles.  Because we had multiple 
measures of both hormones and lipoproteins we were able to more precisely model the 
association between estradiol and lipoprotein cholesterol levels.  Due to the prospective 
nature of this study, we were also able to preserve temporality which had a number of 
benefits.  In particular, we were able to evaluate both acute and persistent effects of estradiol 
on lipoproteins, which yielded further insight into the effects of estrogen on lipoprotein 
metabolism.  
Use of fertility monitors to time clinic visits was a distinguishing feature of this study, 
and a significant improvement over previous studies.  This new technology was used to more 
accurately define menstrual cycle phase, leading to more accurate characterizations of 
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hormonal and lipid fluctuations across the cycle.135  Participants were intensively monitored 
throughout two cycles, and standardized assessment of a wide variety of participant and 
dietary characteristics increased our ability to adjust for potential confounding factors.  In the 
analysis of the association between lipoprotein cholesterol and anovulation, we were able to 
evaluate the possibility of confounding by underlying endocrine disturbances because we had 
measures of several markers of endocrine function.  The prospective design and exclusion 
criteria at baseline strengthened our ability to draw inference among a group of healthy, 
regularly menstruating women.  Not only is this especially important in understanding the 
underlying biological mechanisms between estradiol and lipoprotein metabolism, but we 
were also able to evaluate the association between lipoprotein cholesterol levels and 
anovulation among a group of normally menstruating women with no diagnosed cases of 
PCOS. 
The analysis is set apart by the use of weighted generalized linear mixed effects 
models, which offer several advantages over traditional methods.  First, we were able to 
account for the correlation between and within women throughout the cycle.  Second, we 
were able to adequately adjust for time-modified confounding due to changing hormone 
levels across the cycle.  A special application of marginal structural models (MSMs) was 
used to estimate the controlled direct effects of fiber intake on lipoprotein cholesterol levels 
because they offer several important advantages over standard approaches.  Perhaps the most 
important advantages of the MSM approach are that MSMs can control for time-varying 
confounders affected by prior exposure, as well as accommodate interactions between fiber 
and estrogen.   
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B. Limitations 
There are several limitations worth noting.  First, our study sample population was 
restricted to healthy normally menstruating women in order to exclude potential confounders 
by design, but such restrictions could also limit the generalizability of our findings.  In 
addition, the women in this study were fairly young on average, had a low BMI, were very 
physically active, mostly non-smokers, and not on oral contraceptives, which could further 
limit generalizability.  Despite the fact that we had standardized assessments of a wide 
variety of participant and dietary characteristics which increased our ability to adjust for 
potential confounders, it is still possible that there is unmeasured confounding.  In particular, 
we were not able to adjust for measures of plasma volume which could account for some of 
the observed changes in lipoprotein cholesterol levels across the cycle.  We were also unable 
to directly measure androgen levels, and had to rely on several non-specific markers in our 
assessment of hyperandrogenism.  Ultrasound examinations for presence of polycystic 
ovaries were also unavailable.  Residual confounding is also a possibility, since it can be very 
difficult to capture effects of dietary intake and exercise for example, and some 
misclassification of these covariates is likely.   
Using the fertility monitors to time visits was a significant improvement over 
previous studies, however there is still potential for some misclassification of cycle phase as 
not all LH peaks were captured on the monitor.  We were also limited by a small number of 
anovulatory cycles and an imperfect measurement of ovulation.  The small number of 
anovulatory cycles was partly a consequence of our employment of a conservative definition 
for anovulation, and our strict study inclusion criteria, and limited the power we had to detect 
effects.  While we did have multiple serum hormone measurements to aid in classifying 
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ovulation, along with the use of fertility monitors measuring LH daily in urine, daily 
measures of progesterone and transvaginal ultrasounds (the gold standard) were not 
available, and thus misclassification of ovulation is possible.  While there may be some 
selection bias due to loss to follow-up over the cycle as not all women completed 8 visits per 
cycle, marginal structural models account for this loss to follow-up through inverse 
probability of exposure weighting.   
Finally, while the use of marginal structural models was a significant improvement 
over traditional covariate assessment, they are based on certain strong assumptions such as 
no unmeasured confounding, positivity, correct model specification, and consistency.  These 
assumptions are generally hard to meet and should be taken into consideration when 
interpreting results.115, 120  In the case of effect decomposition, the assumptions of MSMs also 
limit our interpretation of the effects.165  In estimating controlled direct effects we have 
assumed that we can intervene and set estrogen levels to be a certain value.  Although this is 
a possible intervention through the use of oral contraceptives, it is not necessarily a practical 
one.  Despite these limitations, the BioCycle study offers several improvements over 
previous studies and significantly adds to the research in this area. 
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